Frederik Barkhof

List of Publications by Citations

1,466 papers	92,271 citations	142 h-index	253 g-index
1,653 ext. papers	107,515 ext. citations	6.6 avg, IF	7.81 L-index

#	Paper	IF	Citations
1466	Consistent resting-state networks across healthy subjects. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 13848-53	11.5	3210
1465	Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurology, The*, **2013**, 12, 822-38	24.1	2662
1464	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurology, The*, **2018**, 17, 162-173	24.1	2419
1463	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *New England Journal of Medicine*, **2010**, 362, 402-15	59.2	1686
1462	Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*, **2014**, 83, 278-86	6.5	1632
1461	A new rating scale for age-related white matter changes applicable to MRI and CT. *Stroke*, **2001**, 32, 1318-22	6.7	1270
1460	Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. *Journal of Neurology, Neurosurgery and Psychiatry*, **1992**, 55, 967-72	5.5	1021
1459	Reduced resting-state brain activity in the "default network" in normal aging. *Cerebral Cortex*, **2008**, 18, 1856-64	5.1	885
1458	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet, The*, **2001**, 357, 1576-82	40	884
1457	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. *Brain*, **1997**, 120 (Pt 11), 2059-69	11.2	832
1456	A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. *Journal of the Neurological Sciences*, **1993**, 114, 7-12	3.2	744
1455	Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *New England Journal of Medicine*, **2006**, 354, 924-33	59.2	653
1454	Cortical lesions in multiple sclerosis. *Brain*, **1999**, 122 (Pt 1), 17-26	11.2	644
1453	Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. *Neurology*, **1996**, 47, 1531-4	6.5	615
1452	Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. *Annals of Neurology*, **1999**, 46, 747-754	9.4	613
1451	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, **2006**, 67, 1242-9	6.5	601
1450	Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. *Human Brain Mapping*, **2005**, 26, 231-9	5.9	589

1449	Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. *Neurology*, **1998**, 50, 1282-8	6.5	557
1448	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. *Lancet, The*, **2011**, 378, 1779-87	40	522
1447	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. *Lancet Neurology, The*, **2016**, 15, 292-303	24.1	486
1446	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. *NeuroImage* , **2004**, 23, 708-16	7.9	449
1445	The clinico-radiological paradox in multiple sclerosis revisited. *Current Opinion in Neurology*, **2002**, 15, 239-45	7.1	443
1444	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. *Lancet Neurology, The*, **2005**, 4, 281-8	24.1	436
1443	Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. *PLoS ONE*, **2010**, 5, e13788	3.7	434
1442	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 126-35	5.5	430
1441	Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. *Brain*, **2002**, 125, 1676-95	11.2	422
1440	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. *Lancet, The*, **2007**, 370, 389-97	40	417
1439	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. *Lancet, The*, **1999**, 353, 964-9	40	413
1438	Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. *Radiology*, **2005**, 236, 254-60	20.5	400
1437	Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. *Neurology*, **1996**, 47, 1469-76	6.5	392
1436	Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. *Annals of Neurology*, **1996**, 39, 6-16	9.4	387
1435	Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. *Lancet Neurology, The*, **2008**, 7, 903-14	24.1	386
1434	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1939-49	27.4	379
1433	Grey matter pathology in multiple sclerosis. *Lancet Neurology, The*, **2008**, 7, 841-51	24.1	368
1432	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. *Human Molecular Genetics*, **2009**, 18, 767-78	5.6	357

1431	A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. *NeuroImage*, **2003**, 18, 895-907	7.9	347
1430	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. *Nature Reviews Neurology*, **2015**, 11, 597-606	15	321
1429	Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. *Nature Reviews Neurology*, **2009**, 5, 256-66	15	316
1428	Diagnostic criteria for primary progressive multiple sclerosis: A position paper. *Annals of Neurology*, **2000**, 47, 831-835	9.4	313
1427	Vitamin D as an early predictor of multiple sclerosis activity and progression. *JAMA Neurology*, **2014** , 71, 306-14	17.2	312
1426	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. *Lancet Neurology, The*, **2017**, 16, 661-676	24.1	308
1425	Frontal-striatal dysfunction during planning in obsessive-compulsive disorder. *Archives of General Psychiatry*, **2005**, 62, 301-9		300
1424	Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. *Stroke*, **2008**, 39, 1414-20	6.7	299
1423	Regional DTI differences in multiple sclerosis patients. *NeuroImage*, **2009**, 44, 1397-403	7.9	296
1422	Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. *Neurology*, **1995**, 45, 883-8	6.5	291
1421	Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. *Archives of Neurology*, **2012**, 69, 198-207		288
1420	Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. *Journal of Neurology*, **1995**, 242, 557-60	5.5	285
1419	Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. *European Neurology*, **1996**, 36, 268-72	2.1	284
1418	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. *Hippocampus*, **2000**, 10, 398-410	3.5	282
1417	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. *Neurobiology of Aging*, **2013**, 34, 2023-36	5.6	279
1416	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurology, The*, **2009**, 8, 987-97	24.1	279
1415	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. *Lancet Neurology, The*, **2002**, 1, 13-21	24.1	279
1414	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. *BMJ, The*, **2009**, 339, b2477	5.9	277

1413	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. *Brain*, **2015**, 138, 2732-49	11.2	275
1412	Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. *Archives of Neurology*, **2003**, 60, 1073-81		274
1411	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. *Nature Reviews Neurology*, **2015**, 11, 471-82	15	272
1410	Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. *American Journal of Neuroradiology*, **2005**, 26, 572-7	4.4	270
1409	Association between pathological and MRI findings in multiple sclerosis. *Lancet Neurology, The*, **2012**, 11, 349-60	24.1	267
1408	Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. *Neurology*, **1995**, 45, 1684-90	6.5	267
1407	Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. *Stroke*, **2005**, 36, 2116-20	6.7	266
1406	Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. *Journal of Neurology, Neurosurgery and Psychiatry*, **1991**, 54, 683-8	5.5	266
1405	MRI in multiple sclerosis: current status and future prospects. *Lancet Neurology, The*, **2008**, 7, 615-25	24.1	262
1404	Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. *Brain*, **1998**, 121 (Pt 4), 687-97	11.2	256
1403	Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. *Neurology*, **1995**, 45, 255-60	6.5	255
1402	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*, **2012**, 33, 2018-28	5.6	253
1401	White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. *Brain*, **1992**, 115 (Pt 3), 735-48	11.2	252
1400	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. *Lancet Neurology, The*, **2007**, 6, 677-86	24.1	246
1399	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. *Alzheimeris Research and Therapy*, **2017**, 9, 95	9	243
1398	Optimizing patient care and research: the Amsterdam Dementia Cohort. *Journal of Alzheimeris Disease*, **2014**, 41, 313-27	4.3	243
1397	Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. *Stroke*, **2003**, 34, 441-5	6.7	240
1396	Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. *Neurology*, **2009**, 72, 999-1007	6.5	238

1395	Prevalence and severity of microbleeds in a memory clinic setting. *Neurology*, **2006**, 66, 1356-60	6.5	238
1394	Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. *Stroke*, **2006**, 37, 836-40	6.7	236
1393	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. *Neurology*, **2010**, 74, 1868-76	6.5	234
1392	Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. *Neurology*, **2004**, 62, 226-33	6.5	234
1391	The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. *Neurology*, **1999**, 53, 448-56	6.5	229
1390	Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications. *Radiology*, **2016**, 281, 337-356	6.5	225
1389	Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. *Brain*, **1993**, 116 (Pt 5), 1077-94	11.2	224
1388	Resting-state functional MR imaging: a new window to the brain. *Radiology*, **2014**, 272, 29-49	20.5	223
1387	Visual assessment of posterior atrophy development of a MRI rating scale. *European Radiology*, **2011**, 21, 2618-25	8	223
1386	Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. *Annals of Neurology*, **1999**, 45, 695-703	9.4	222
1385	The clinical profile of right temporal lobe atrophy. *Brain*, **2009**, 132, 1287-98	11.2	220
1384	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2004**, 364, 1489-96	40	215
1383	Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. *Brain*, **2001**, 124, 1635-45	11.2	214
1382	The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. *Brain*, **2000**, 123 (Pt 11), 2256-63	11.2	214
1381	Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. *Neurology*, **2011**, 76, 418-24	6.5	212
1380	Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. *Neurology*, **2005**, 64, 987-91	6.5	211
1379	Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. *Annals of Neurology*, **1999**, 46, 747-54	9.4	211
1378	Magnetic resonance imaging pattern recognition in hypomyelinating disorders. *Brain*, **2010**, 133, 2971-82	11.2	210

1377	Brain atrophy and lesion load predict long term disability in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1082-91	5.5	209
1376	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. *Neuroradiology*, **2007**, 49, 967-76	3.2	209
1375	White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. *European Neurology*, **1998**, 39, 80-9	2.1	208
1374	Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. *Neurology*, **1997**, 49, 351-7	6.5	205
1373	Extensive hippocampal demyelination in multiple sclerosis. *Journal of Neuropathology and Experimental Neurology*, **2007**, 66, 819-27	3.1	203
1372	GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. *Diabetes*, **2014**, 63, 4186-96	0.9	198
1371	Lack of association between antimyelin antibodies and progression to multiple sclerosis. *New England Journal of Medicine*, **2007**, 356, 371-8	59.2	197
1370	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. *Brain*, **2008**, 131, 3286-98	11.2	195
1369	Resting state networks change in clinically isolated syndrome. *Brain*, **2010**, 133, 1612-21	11.2	194
1368	White matter tract integrity in aging and Alzheimer's disease. *Human Brain Mapping*, **2009**, 30, 1051-9	5.9	194
1367	MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". *Lancet Neurology, The*, **2006**, 5, 841-52	24.1	194
1366	Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. *American Journal of Neuroradiology*, **2006**, 27, 455-61	4.4	194
1365	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge. *NeuroImage*, **2015**, 111, 562-79	7.9	193
1364	Accumulation of cortical lesions in MS: relation with cognitive impairment. *Multiple Sclerosis Journal* , **2009**, 15, 708-14	5	191
1363	MRI criteria for MS in patients with clinically isolated syndromes. *Neurology*, **2010**, 74, 427-34	6.5	187
1362	CT and MRI rating of white matter lesions. *Cerebrovascular Diseases*, **2002**, 13 Suppl 2, 31-6	3.2	187
1361	Deep gray matter volume loss drives disability worsening in multiple sclerosis. *Annals of Neurology*, **2018**, 83, 210-222	9.4	185
1360	Frontostriatal system in planning complexity: a parametric functional magnetic resonance version of Tower of London task. *NeuroImage*, **2003**, 18, 367-74	7.9	185

1359	Spinal-cord MRI in multiple sclerosis. *Lancet Neurology, The*, **2003**, 2, 555-62	24.1	181
1358	Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. *Stroke*, **2009**, 40, 3455-60	6.7	179
1357	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. *Lancet Neurology, The*, **2011**, 10, 520-9	24.1	178
1356	Imaging markers for Alzheimer disease: which vs how. *Neurology*, **2013**, 81, 487-500	6.5	173
1355	Postmortem verification of MS cortical lesion detection with 3D DIR. *Neurology*, **2012**, 78, 302-8	6.5	173
1354	FMRI of visual encoding: reproducibility of activation. *Human Brain Mapping*, **2000**, 9, 156-64	5.9	173
1353	Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. *American Journal of Neuroradiology*, **1998**, 19, 675-83	4.4	173
1352	Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. *Radiology*, **2013**, 267, 221-30	20.5	170
1351	Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. *Annals of Neurology*, **1999**, 46, 79-87	9.4	169
1350	Patterns of Cerebral Atrophy in Dementia with Lewy Bodies Using Voxel-Based Morphometry. *NeuroImage*, **2002**, 17, 618-630	7.9	167
1349	Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. *NeuroImage*, **2005**, 24, 898-909	7.9	164
1348	Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. *Brain*, **2016**, 139, 115-26	11.2	161
1347	Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. *Brain*, **1995**, 118 (Pt 6), 1601-12	11.2	157
1346	PML in a patient treated with dimethyl fumarate from a compounding pharmacy. *New England Journal of Medicine*, **2013**, 368, 1658-9	59.2	155
1345	Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. *Archives of Internal Medicine*, **2007**, 167, 81-8		154
1344	Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. *Lancet Neurology, The*, **2014**, 13, 807-22	24.1	153
1343	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. *Lancet Neurology, The*, **2012**, 11, 33-41	24.1	153
1342	MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. *Neurology*, **2006**, 66, 1384-9	6.5	152

1341	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. *Brain*, **2019**, 142, 1858-1875	11.2	150
1340	White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. *Neurology*, **2004**, 63, 139-44	6.5	150
1339	MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). *Multiple Sclerosis Journal*, **1999**, 5, 283-6	5	150
1338	Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images. *NeuroImage: Clinical*, **2015**, 8, 367-75	5.3	149
1337	Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. *Neurology*, **2004**, 62, 1533-9	6.5	149
1336	Subcortical atrophy and cognition: sex effects in multiple sclerosis. *Neurology*, **2012**, 79, 1754-61	6.5	148
1335	Incident lacunes influence cognitive decline: the LADIS study. *Neurology*, **2011**, 76, 1872-8	6.5	148
1334	Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. *European Neurology*, **1997**, 37, 95-9	2.1	148
1333	Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. *Brain*, **2008**, 131, 800-7	11.2	148
1332	Primary and transitional progressive MS: a clinical and MRI cross-sectional study. *Neurology*, **1999**, 52, 839-45	6.5	148
1331	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. *Lancet Neurology, The*, **2013**, 12, 233-43	24.1	146
1330	Progression of regional grey matter atrophy in multiple sclerosis. *Brain*, **2018**, 141, 1665-1677	11.2	146
1329	Within-subject reproducibility of visual activation patterns with functional magnetic resonance imaging using multislice echo planar imaging. *Magnetic Resonance Imaging*, **1998**, 16, 105-13	3.3	145
1328	Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. *Neurobiology of Disease*, **2005**, 20, 953-60	7.5	143
1327	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. *Human Brain Mapping*, **2015**, 36, 4421-37	5.9	142
1326	Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. *Annals of Neurology*, **1998**, 43, 332-9	9.4	142
1325	Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection. *Radiology*, **2004**, 230, 529-36	20.5	142
1324	Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. *Journal of the Neurological Sciences*, **1998**, 160, 164-70	3.2	141

1323	MR venography of multiple sclerosis. *American Journal of Neuroradiology*, **2000**, 21, 1039-42	4.4	141
1322	Functional MR imaging in Alzheimer's disease during memory encoding. *American Journal of Neuroradiology*, **2000**, 21, 1869-75	4.4	141
1321	Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. *Brain*, **2001**, 124, 154-66	11.2	140
1320	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. *Alzheimeris and Dementia*, **2011**, 7, 474-485.e4	1.2	139
1319	Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. *Multiple Sclerosis Journal*, **2011**, 17, 1098-106	5	139
1318	Longitudinal cognitive decline in subcortical ischemic vascular disease--the LADIS Study. *Cerebrovascular Diseases*, **2009**, 27, 384-91	3.2	139
1317	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. *Neurobiology of Aging*, **2007**, 28, 1070-4	5.6	139
1316	Combining shape and connectivity analysis: an MRI study of thalamic degeneration in Alzheimer's disease. *NeuroImage*, **2010**, 49, 1-8	7.9	138
1315	The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. *Neurology*, **2007**, 69, 1521-7	6.5	138
1314	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. *Alzheimeris and Dementia*, **2015**, 11, 111-25	1.2	137
1313	Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs). *NeuroImage: Clinical*, **2013**, 3, 462-9	5.3	137
1312	Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. *Diabetologia*, **2006**, 49, 2474-80	10.3	137
1311	Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. *Radiology*, **2006**, 240, 811-20	20.5	136
1310	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. *Brain*, **2016**, 139, 1211-25	11.2	135
1309	Endogenous cortisol level interacts with noradrenergic activation in the human amygdala. *Neurobiology of Learning and Memory*, **2007**, 87, 57-66	3.1	134
1308	Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. *American Journal of Neuroradiology*, **2008**, 29, 944-9	4.4	133
1307	Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. *Neurology*, **2008**, 70, 1150-1	6.5	132
1306	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. *Neurology*, **2013**, 80, 1048-56	6.5	131

1305	Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. *Radiology*, **2002**, 223, 46-56	20.5	130
1304	Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. *Neuroscience Letters*, **2000**, 285, 231-3	3.3	129
1303	A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. *Annals of Neurology*, **2003**, 53, 252-8	9.4	128
1302	Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. *Archives of Neurology*, **2002**, 59, 1572-6		128
1301	Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. *Neurology*, **2002**, 59, 1766-71	6.5	127
1300	Microglial activation in Alzheimer's disease: an (R)-[□□C]PK11195 positron emission tomography study. *Neurobiology of Aging*, **2013**, 34, 128-36	5.6	126
1299	Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography. *Annals of Surgery*, **1999**, 230, 31-7	7.8	125
1298	Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. *Annals of Neurology*, **2006**, 59, 504-11	9.4	124
1297	Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. *Neurology*, **2015**, 84, 776-83	6.5	123
1296	Visual association encoding activates the medial temporal lobe: a functional magnetic resonance imaging study. *Hippocampus*, **1997**, 7, 594-601	3.5	123
1295	Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. *Journal of Magnetic Resonance Imaging*, **2006**, 23, 628-36	5.6	123
1294	Normal gyration and sulcation in preterm and term neonates: appearance on MR images. *Radiology*, **1996**, 200, 389-96	20.5	122
1293	Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. *Stroke*, **2003**, 34, 1907-12	6.7	122
1292	MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. *Magnetic Resonance in Medicine*, **2005**, 53, 256-66	4.4	122
1291	Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. *Neurology*, **2013**, 80, 1025-32	6.5	121
1290	Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. *European Radiology*, **2010**, 20, 1675-83	8	121
1289	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2014-22	5.6	120
1288	Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. *Archives of Neurology*, **2009**, 66, 601-9		120

1287	Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. *Annals of Neurology*, **1998**, 43, 499-506	9.4	120
1286	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 439-42	5.5	119
1285	Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. *Radiology*, **2000**, 217, 869-76	20.5	119
1284	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. *Lancet Neurology, The*, **2017**, 16, 965-975	24.1	118
1283	Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. *Neurology*, **2013**, 80, 69-75	6.5	118
1282	Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?. *Neurology*, **2010**, 74, 1033-40	6.5	118
1281	Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2002**, 73, 665-71	5.5	118
1280	Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. *Neurology*, **2017**, 89, 269-278	6.5	117
1279	The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. *Radiology*, **2004**, 233, 531-40	20.5	117
1278	Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. *NeuroImage*, **2012**, 61, 1484-94	7.9	116
1277	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 990-1000	8.8	116
1276	Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. *Archives of Neurology*, **2007**, 64, 76-80		116
1275	Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. *American Journal of Roentgenology*, **1992**, 159, 1041-7	5.4	116
1274	Cerebral Microbleeds: Imaging and Clinical Significance. *Radiology*, **2018**, 287, 11-28	20.5	115
1273	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. *JAMA Neurology*, **2014**, 71, 855-62	17.2	113
1272	Optimizing the association between disability and biological markers in MS. *Neurology*, **2001**, 57, 1253-8	6.5	113
1271	The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. *Multiple Sclerosis Journal*, **2002**, 8, 532-3	5	113
1270	Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. *Stroke*, **2009**, 40, 1269-74	6.7	112

1269	Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. *NeuroImage*, **2005**, 26, 1078-85	7.9	112
1268	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. *Lancet Neurology, The*, **2005**, 4, 341-8	24.1	112
1267	MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. *Magnetic Resonance in Medicine*, **2006**, 55, 478-83	4.4	111
1266	Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. *Neurology*, **2003**, 60, 219-23	6.5	111
1265	Microglial activation in healthy aging. *Neurobiology of Aging*, **2012**, 33, 1067-72	5.6	110
1264	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. *Neurology*, **2012**, 79, 1809-16	6.5	110
1263	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 468-75	5.5	109
1262	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. *Radiology*, **2013**, 269, 542-552	20.5	109
1261	Resting-state networks in awake five- to eight-year old children. *Human Brain Mapping*, **2012**, 33, 1189-201	5.9	108
1260	Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. *Journal of Nuclear Medicine*, **2009**, 50, 191-7	8.9	108
1259	Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. *Multiple Sclerosis Journal*, **2005**, 11, 524-31	5	108
1258	Model-free group analysis shows altered BOLD FMRI networks in dementia. *Human Brain Mapping*, **2009**, 30, 256-66	5.9	107
1257	Chronic cerebrospinal venous insufficiency and multiple sclerosis. *Annals of Neurology*, **2010**, 67, 286-90	9.4	107
1256	Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. *Radiology*, **2008**, 248, 590-8	20.5	107
1255	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. *Current Medical Research and Opinion*, **2008**, 24, 2561-74	2.5	106
1254	Functional connectivity and cognitive decline over 3 years in Parkinson disease. *Neurology*, **2014**, 83, 2046-53	6.5	105
1253	Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. *Neurology*, **1991**, 41, 1219-22	6.5	105
1252	Imaging of white matter lesions. *Cerebrovascular Diseases*, **2002**, 13 Suppl 2, 21-30	3.2	104

1251	Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. *Stroke*, **2011**, 42, 1894-900	6.7	103
1250	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. *Journal of Neurology*, **2006**, 253, 1189-96	5.5	101
1249	Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. *Brain*, **2016**, 139, 1472-81	11.2	100
1248	Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: an MEG source-space study. *NeuroImage*, **2014**, 88, 308-18	7.9	100
1247	Neuroplasticity and functional recovery in multiple sclerosis. *Nature Reviews Neurology*, **2012**, 8, 635-46	15	100
1246	Hippocampal atrophy in Alzheimer disease: age matters. *Neurology*, **2006**, 66, 236-8	6.5	100
1245	Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. *Neurology: Neuroimmunology and NeuroInflammation*, **2014**, 1, e18	9.1	99
1244	MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. *Stroke*, **2009**, 40, 492-8	6.7	99
1243	Resting-state brain networks in type 1 diabetic patients with and without microangiopathy and their relation to cognitive functions and disease variables. *Diabetes*, **2012**, 61, 1814-21	0.9	99
1242	Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. *Neurology*, **2012**, 78, 1785-92	6.5	98
1241	Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. *Neurology*, **1997**, 49, 1682-8	6.5	98
1240	Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals. *Radiology*, **2015**, 274, 490-9	20.5	97
1239	Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. *Neurology*, **2010**, 74, 1954-60	6.5	97
1238	Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. *Radiology*, **2009**, 253, 174-83	20.5	97
1237	Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. *Neurology*, **2015**, 84, 508-15	6.5	96
1236	Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study. *Brain*, **2006**, 129, 141-57	11.2	96
1235	White matter lesions and hippocampal atrophy in Alzheimer's disease. *Neurology*, **2004**, 62, 310-2	6.5	96
1234	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. *Annals of Neurology*, **2003**, 53, 718-24	9.4	96

1233	Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. *Archives of Neurology*, **2001**, 58, 76-81		96
1232	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. *Nature Reviews Neurology*, **2018**, 14, 199-213	15	95
1231	Structural and functional hippocampal changes in multiple sclerosis patients with intact memory function. *Radiology*, **2010**, 255, 595-604	20.5	95
1230	No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 429-35	5.5	95
1229	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. *Lancet Neurology, The*, **2020**, 19, 951-962	24.1	95
1228	Hippocampal volume change measurement: quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. *NeuroImage*, **2014**, 92, 169-81	7.9	94
1227	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. *Lancet Neurology, The*, **2006**, 5, 221-7	24.1	94
1226	Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI. *NeuroImage*, **2006**, 32, 1205-15	7.9	94
1225	Unusual variants of Alexander's disease. *Annals of Neurology*, **2005**, 57, 327-38	9.4	94
1224	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. *Nature Reviews Neurology*, **2015**, 11, 676-86	15	93
1223	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. *Neurology*, **2015**, 84, 784-93	6.5	93
1222	Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. *Journal of Clinical Oncology*, **2013**, 31, 3378-88	7.7	93
1221	Test-retest analysis with functional MR of the activated area in the human visual cortex. *American Journal of Neuroradiology*, **1997**, 18, 1317-22	4.4	93
1220	Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. *NeuroImage*, **2004**, 23, 1450-9	7.9	92
1219	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. *Brain*, **2012**, 135, 2115-25	11.2	91
1218	EFNS task force: the use of neuroimaging in the diagnosis of dementia. *European Journal of Neurology*, **2012**, 19, e131-40, 1487-501	6	90
1217	Visual rating scales for age-related white matter changes (leukoaraiosis): can the heterogeneity be reduced?. *Stroke*, **2002**, 33, 2827-33	6.7	90
1216	The role of MRI as a surrogate outcome measure in multiple sclerosis. *Multiple Sclerosis Journal*, **2002**, 8, 40-51	5	89

1215	A multicenter measurement of magnetization transfer ratio in normal white matter. *Journal of Magnetic Resonance Imaging*, **1999**, 9, 441-6	5.6	89
1214	A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. *Neurology*, **1992**, 42, 63-7	6.5	89
1213	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 410-8	5.5	88
1212	Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. *Journal of the Neurological Sciences*, **2011**, 311, 44-9	3.2	88
1211	Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. *Diabetologia*, **2007**, 50, 1763-9	10.3	88
1210	The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. *Stroke*, **2007**, 38, 3182-5	6.7	88
1209	Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities and Results of the WMH Segmentation Challenge. *IEEE Transactions on Medical Imaging*, **2019**, 38, 2556-2568	11.7	87
1208	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. *Neuro-Oncology*, **2015**, 17, 160-6	1	87
1207	Structural degree predicts functional network connectivity: a multimodal resting-state fMRI and MEG study. *NeuroImage*, **2014**, 97, 296-307	7.9	87
1206	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 669-75	5.6	87
1205	The functional basis of ocular dominance: functional MRI (fMRI) findings. *Neuroscience Letters*, **1996** , 221, 1-4	3.3	87
1204	Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. *Multiple Sclerosis Journal*, **2011**, 17, 1202-10	5	86
1203	Retinoblastoma: MR imaging parameters in detection of tumor extent. *Radiology*, **2005**, 235, 197-207	20.5	86
1202	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 478-83	5.5	85
1201	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 1225-33	5.5	84
1200	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. *Nature Reviews Neurology*, **2018**, 14, 75-93	15	84
1199	Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. *Human Brain Mapping*, **2014**, 35, 2383-93	5.9	84
1198	Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 593-600	5	84

1197	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. *Journal of Neurology*, **2013**, 260, 2458-71	5.5	83
1196	Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. *Annals of Neurology*, **2008**, 63, 790-3	9.4	83
1195	Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. *Annals of Neurology*, **1992**, 32, 834-5	9.4	83
1194	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 547-51	5.5	82
1193	One year follow up study of primary and transitional progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 713-8	5.5	82
1192	MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. *Lancet Neurology, The*, **2015**, 14, 443-54	24.1	81
1191	Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data. *Human Brain Mapping*, **2013**, 34, 52-61	5.9	81
1190	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. *Multiple Sclerosis Journal*, **2014**, 20, 72-80	5	81
1189	Fast eigenvector centrality mapping of voxel-wise connectivity in functional magnetic resonance imaging: implementation, validation, and interpretation. *Brain Connectivity*, **2012**, 2, 265-74	2.7	81
1188	Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. *Neurology*, **2009**, 72, 595-601	6.5	81
1187	Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. *European Journal of Pharmacology*, **2008**, 585, 88-96	5.3	81
1186	MS functional composite: relation to disease phenotype and disability strata. *Neurology*, **2000**, 54, 1233-9	8.5	81
1185	Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. *Journal of the Neurological Sciences*, **1994**, 122, 6-14	3.2	81
1184	Differential diagnosis of neurodegenerative diseases using structural MRI data. *NeuroImage: Clinical*, **2016**, 11, 435-449	5.3	81
1183	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. *Neurology*, **2013**, 80, 359-65	6.5	80
1182	Single-subject grey matter graphs in Alzheimer's disease. *PLoS ONE*, **2013**, 8, e58921	3.7	80
1181	The limits of functional reorganization in multiple sclerosis. *Neurology*, **2010**, 74, 1246-7	6.5	80
1180	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. *Diabetic Medicine*, **2007**, 24, 166-71	3.5	80

1179	Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 419-24	5.5	79
1178	The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. *Journal of Neurology*, **2012**, 259, 147-54	5.5	79
1177	Interobserver variability in the radiological assessment of response to chemotherapy in glioma. *Neurology*, **2003**, 60, 826-30	6.5	79
1176	Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. *Multiple Sclerosis Journal*, **2000**, 6, 280-5	5	79
1175	P07.08 Higher functional hub load at diagnosis is associated with shorter survival in glioma patients. *Neuro-Oncology*, **2016**, 18, iv35-iv35	1	78
1174	HOUT-14. TIME TO PROGRESSION AND VOLUME AT PROGRESSION DEPEND ON DEFINITION OF PROGRESSION IN GLIOBLASTOMA. *Neuro-Oncology*, **2017**, 19, vi108-vi109	1	78
1173	P16.12BRAIN LOCATIONS INVOLVED IN BASELINE COGNITIVE FUNCTIONING OF PATIENTS WITH GLIOMA BEFORE THERAPY. *Neuro-Oncology*, **2014**, 16, ii80-ii81	1	78
1172	The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. *Multiple Sclerosis Journal*, **2013**, 19, 1826-40	5	78
1171	Reply:. *American Journal of Neuroradiology*, **2012**, 33, E98-E98	4.4	78
1170	Human gray matter: feasibility of single-slab 3D double inversion-recovery high-spatial-resolution MR imaging. *Radiology*, **2006**, 241, 873-9	20.5	78
1169	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. *Neurology*, **2016**, 87, 978-87	8.5	78
1168	P01.062 Probability maps of glioblastoma indicate variation in surgical decisions between twelve surgical teams. *Neuro-Oncology*, **2018**, 20, iii243-iii244	1	78
1167	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. *Neurobiology of Aging*, **2010**, 31, 758-64	5.6	77
1166	Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. *European Radiology*, **2008**, 18, 2311-20	8	77
1165	Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. *Neurology*, **1998**, 50, 238-44	6.5	77
1164	Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. *Neurology*, **2008**, 70, 1836-41	6.5	76
1163	In vivo MR imaging of hippocampal lesions in multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2008**, 27, 726-31	5.6	76
1162	Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 491-6	5.5	76

1161	Leukoaraiosis predicts hidden global functioning impairment in nondisabled older people: the LADIS (Leukoaraiosis and Disability in the Elderly) Study. *Journal of the American Geriatrics Society*, **2006**, 54, 1095-101	5.6	76
1160	The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. *Neurology*, **2003**, 60, 853-60	6.5	76
1159	Management of obstetric brachial plexus lesions: state of the art and future developments. *Childis Nervous System*, **2000**, 16, 638-44	1.7	76
1158	Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. *Journal of Neurology*, **2008**, 255, 1302-8	5.5	75
1157	Identifying confounds to increase specificity during a "no task condition". Evidence for hippocampal connectivity using fMRI. *NeuroImage*, **2003**, 20, 1236-45	7.9	75
1156	Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. *Metabolism: Clinical and Experimental*, **1999**, 48, 233-8	12.7	75
1155	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. *Lancet Neurology, The*, **2019**, 18, 185-197	24.1	74
1154	Inflammatory biomarkers in Alzheimer's disease plasma. *Alzheimeris and Dementia*, **2019**, 15, 776-787	1.2	74
1153	Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. *Brain*, **2018**, 141, 2605-2618	11.2	74
1152	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. *European Radiology*, **2009**, 19, 2826-33	8	74
1151	Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. *Journal of the Neurological Sciences*, **2001**, 184, 155-62	3.2	74
1150	White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. *Stroke*, **2012**, 43, 2643-7	6.7	73
1149	Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. *Archives of Neurology*, **2006**, 63, 614-9		73
1148	Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 304-7	5.5	73
1147	Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **1999**, 354, 1675-86	5.8	73
1146	Diagnostic criteria for primary progressive multiple sclerosis: a position paper. *Annals of Neurology*, **2000**, 47, 831-5	9.4	73
1145	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. *Journal of Neurology*, **2013**, 260, 2023-32	5.5	72
1144	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. *Neurobiology of Aging*, **2012**, 33, 2272-81	5.6	72

1143	Visualizing brain activation during planning: the tower of London test adapted for functional MR imaging. *American Journal of Neuroradiology*, **2000**, 21, 1407-14	4.4	72
1142	An algorithmic approach to structural imaging in dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 692-8	5.5	71
1141	Childhood white matter disorders: quantitative MR imaging and spectroscopy. *Radiology*, **2006**, 241, 510-7	20.5	71
1140	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1497-500	5.5	71
1139	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. *JAMA Neurology*, **2018**, 75, 1062-1070	17.2	70
1138	Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study. *Stroke*, **2010**, 41, e402-8	6.7	70
1137	MRI-defined subcortical ischemic vascular disease: baseline clinical and neuropsychological findings. The LADIS Study. *Cerebrovascular Diseases*, **2009**, 27, 336-44	3.2	70
1136	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. *Neurology*, **2007**, 69, 1491-7	6.5	70
1135	Visual activation patterns in patients with optic neuritis: an fMRI pilot study. *Neurology*, **1998**, 50, 1896-9	6.5	70
1134	Cerebral perfusion in the predementia stages of Alzheimer's disease. *European Radiology*, **2016**, 26, 506-14	5.4	69
1133	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. *Neurobiology of Aging*, **2013**, 34, 2003-13	5.6	69
1132	Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. *Stroke*, **2009**, 40, 773-9	6.7	69
1131	Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. *Journal of Neuroimmunology*, **2004**, 155, 155-60	3.5	69
1130	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. *Nature Reviews Neurology*, **2020**, 16, 171-182	15	68
1129	Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. *Neurology*, **2010**, 75, 2071-8	6.5	68
1128	Gender-related differences in functional connectivity in multiple sclerosis. *Multiple Sclerosis Journal* , **2012**, 18, 164-73	5	68
1127	MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. *American Journal of Neuroradiology*, **1997**, 18, 1041-8	4.4	68
1126	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. *Neurology*, **2018**, 90, e149-e156	6.5	68

1125	Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study. *Human Brain Mapping*, **2015**, 36, 603-18	5.9	67
1124	MRI assessment of iron deposition in multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2011**, 34, 13-21	5.6	67
1123	Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials. *Neurology*, **1997**, 49, 371-7	6.5	67
1122	What drives MRI-measured cortical atrophy in multiple sclerosis?. *Multiple Sclerosis Journal*, **2015**, 21, 1280-90	5	66
1121	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. *Lancet Neurology, The*, **2018**, 17, 133-142	24.1	66
1120	Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. *European Radiology*, **2014**, 24, 841-9	8	66
1119	The spatial distribution of age-related white matter changes as a function of vascular risk factors--results from the LADIS study. *NeuroImage*, **2012**, 60, 1597-607	7.9	66
1118	Intercenter differences in diffusion tensor MRI acquisition. *Journal of Magnetic Resonance Imaging*, **2010**, 31, 1458-68	5.6	66
1117	Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. *Multiple Sclerosis Journal*, **2000**, 6, 99-104	5	66
1116	Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. *NeuroImage*, **2002**, 17, 618-30	7.9	66
1115	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. *European Radiology*, **2015**, 25, 3050-9	8	65
1114	Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study. *Human Brain Mapping*, **2016**, 37, 1627-44	5.9	65
1113	Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. *Brain*, **2019**, 142, 2276-2287	11.2	65
1112	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. *European Radiology*, **2017**, 27, 1169-1175	8	65
1111	Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. *Diabetes, Obesity and Metabolism*, **2015**, 17, 878-86	6.7	65
1110	On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. *Stroke*, **2008**, 39, 3083-5	6.7	65
1109	A three-year, multi-parametric MRI study in patients at presentation with CIS. *Journal of Neurology*, **2008**, 255, 683-91	5.5	65
1108	Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. *Neurology*, **2003**, 60, 1904-8	6.5	65

1107	T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. *Brain*, **2001**, 124, 1396-402	11.2	65
1106	Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. *Journal of the Neurological Sciences*, **1999**, 163, 74-80	3.2	65
1105	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. *Brain*, **2019**, 142, 2787-2799	11.2	64
1104	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. *Alzheimeris and Dementia*, **2017**, 13, 531-540	1.2	64
1103	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. *Journal of Neurology*, **1997**, 244, 76-84	5.5	64
1102	Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression. *Cerebrovascular Diseases*, **2008**, 25, 247-53	3.2	64
1101	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 425-32	5.5	63
1100	MRI pattern in asymptomatic natalizumab-associated PML. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 793-8	5.5	63
1099	Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease. *NeuroImage*, **2013**, 66, 28-35	7.9	63
1098	High field MRI in the diagnosis of multiple sclerosis: high field-high yield?. *Neuroradiology*, **2009**, 51, 279-92	3.2	63
1097	Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study. *Journal of Neurology*, **1998**, 245, 153-8	5.5	63
1096	Tumor-volume changes after radiosurgery for vestibular schwannoma: implications for follow-up MR imaging protocol. *American Journal of Neuroradiology*, **2008**, 29, 906-10	4.4	63
1095	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. *Journal of Neurology*, **2008**, 255, 1-10	5.5	63
1094	A paced visual serial addition test for fMRI. *Journal of the Neurological Sciences*, **2003**, 213, 29-34	3.2	63
1093	Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. *Neurology*, **2001**, 56, 215-9	6.5	63
1092	Phase-Contrast Cine Mr Imaging of Normal Aqueductal CSF Flow: Effect of Aging and Relation to CSF Void on Modulus MR. *Acta Radiologica*, **1994**, 35, 123-130	2	63
1091	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusion-Tensor and Magnetic Resonance Imaging Data. *Journal of Neuroimaging*, **2015**, 25, 738-47	2.8	62
1090	Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. *Radiology*, **2014**, 270, 205-11	20.5	62

1089	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. *Neurology*, **2012**, 79, 763-9	6.5	62
1088	Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. *European Radiology*, **2012**, 22, 221-31	8	62
1087	Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities. *American Journal of Neuroradiology*, **2008**, 29, 1296-301	4.4	62
1086	Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. *European Journal of Neurology*, **2008**, 15, 113-22	6	61
1085	Changes in brain electrical activity during extended continuous word recognition. *NeuroImage*, **2005**, 26, 952-9	7.9	61
1084	Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2003**, 17, 389-97	5.6	61
1083	Increased default-mode network centrality in cognitively impaired multiple sclerosis patients. *Neurology*, **2017**, 88, 952-960	6.5	60
1082	Differential patterns of spinal cord and brain atrophy in NMO and MS. *Neurology*, **2015**, 84, 1465-72	6.5	60
1081	Prevalence of cortical superficial siderosis in a memory clinic population. *Neurology*, **2014**, 82, 698-704	6.5	60
1080	Disruption of structural and functional networks in long-standing multiple sclerosis. *Human Brain Mapping*, **2014**, 35, 5946-61	5.9	60
1079	Neuroimaging in Dementia **2011**,		60
1078	Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. *Multiple Sclerosis Journal*, **2009**, 15, 180-8	5	60
1077	Neurological signs in relation to type of cerebrovascular disease in vascular dementia. *Stroke*, **2008**, 39, 317-22	6.7	60
1076	The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. *Neurology*, **2001**, 57, 2185-90	6.5	60
1075	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2488-94	5.6	59
1074	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. *Alzheimeris and Dementia*, **2015**, 11, 1191-201	1.2	59
1073	Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 1183-9	5.5	59
1072	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. *Neurology*, **2009**, 73, 935-40	6.5	59

1071	Does high-field MR imaging improve cortical lesion detection in multiple sclerosis?. *Journal of Neurology*, **2008**, 255, 183-91	5.5	59
1070	Anterior medial temporal lobe activation during attempted retrieval of encoded visuospatial scenes: an event-related fMRI study. *NeuroImage*, **2001**, 14, 67-76	7.9	59
1069	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. *NeuroImage*, **2016**, 124, 442-454	7.9	58
1068	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 235-43	5.5	58
1067	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. *JAMA Neurology*, **2017**, 74, 1481-1491	17.2	58
1066	Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. *Diabetologia*, **2015**, 58, 2688-98	10.3	58
1065	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 627.e1-627.e12	5.6	58
1064	Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. *Journal of Neurology*, **2008**, 255, 480-7	5.5	58
1063	Corpus callosum size correlates with asymmetric performance on a dichotic listening task in healthy aging but not in Alzheimer's disease. *Neuropsychologia*, **2006**, 44, 208-17	3.2	58
1062	Microvascular disease in type 1 diabetes alters brain activation: a functional magnetic resonance imaging study. *Diabetes*, **2006**, 55, 334-40	0.9	58
1061	Clinical significance of corpus callosum atrophy in a mixed elderly population. *Neurobiology of Aging* , **2007**, 28, 955-63	5.6	58
1060	Cognitive and clinical dysfunction, altered MEG resting-state networks and thalamic atrophy in multiple sclerosis. *PLoS ONE*, **2013**, 8, e69318	3.7	58
1059	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. *Alzheimeris and Dementia*, **2019**, 15, 644-654	1.2	57
1058	Altered cerebrovascular reactivity velocity in mild cognitive impairment and Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 33-41	5.6	57
1057	What explains gray matter atrophy in long-standing multiple sclerosis?. *Radiology*, **2014**, 272, 832-42	20.5	57
1056	Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. *Human Brain Mapping*, **2012**, 33, 2268-80	5.9	57
1055	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. *Nature Reviews Neurology*, **2011**, 8, 13-21	15	57
1054	Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. *Journal of Magnetic Resonance Imaging*, **2004**, 20, 366-71	5.6	57

1053	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. *Multiple Sclerosis Journal*, **2019**, 25, 1915-1925	5	57
1052	The hippocampus in multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 918-926	24.1	57
1051	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. *Alzheimeris Research and Therapy*, **2018**, 10, 76	9	56
1050	Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability. *Multiple Sclerosis Journal*, **2014**, 20, 1860-5	5	56
1049	Clinical correlations of brain lesion distribution in multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 768-73	5.6	56
1048	Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study. *Human Brain Mapping*, **2015**, 36, 2809-25	5.9	55
1047	Magnetic resonance imaging predictors of cognition in mild cognitive impairment. *Archives of Neurology*, **2007**, 64, 1023-8		55
1046	Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis. *Neuropathology and Applied Neurobiology*, **2004**, 30, 106-17	5.2	55
1045	Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. *Multiple Sclerosis Journal*, **2004**, 10, 41-6	5	55
1044	Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. *Brain*, **1999**, 122 (Pt 8), 1589-95	11.2	55
1043	Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study. *Human Brain Mapping*, **2014**, 35, 5799-814	5.9	54
1042	Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 1351-6	5.5	54
1041	Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. *Journal of Alzheimeris Disease*, **2012**, 29, 319-27	4.3	54
1040	Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. *Alzheimeris Research and Therapy*, **2020**, 12, 118	9	54
1039	Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. *American Journal of Neuroradiology*, **2005**, 26, 442-6	4.4	54
1038	Diffusion changes predict cognitive and functional outcome: the LADIS study. *Annals of Neurology*, **2013**, 73, 576-83	9.4	53
1037	EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. *European Journal of Neurology*, **2006**, 13, 313-25	6	53
1036	Diffuse signal abnormalities in the spinal cord in multiple sclerosis: direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology. *Annals of Neurology*, **2002**, 51, 652-6	9.4	53

1035	Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. *Annals of Neurology*, **2005**, 58, 781-3	9.4	53
1034	Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis. *Archives of Neurology*, **1998**, 55, 793-8		53
1033	Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. *Archives of Neurology*, **1999**, 56, 345-51		53
1032	Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. *Stroke*, **2020**, 51, 170-178	6.7	53
1031	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. *Radiology*, **2016**, 279, 838-48	20.5	52
1030	Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 412-7	5	52
1029	Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR. *American Journal of Neuroradiology*, **2013**, 34, 791-6	4.4	52
1028	Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. *Radiology*, **2010**, 255, 154-63	20.5	52
1027	Intracranial aneurysms treated with coil placement: test characteristics of follow-up MR angiography--multicenter study. *Radiology*, **2010**, 256, 209-18	20.5	52
1026	Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. *Neurology*, **2008**, 70, 1134-40	6.5	52
1025	An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. *Multiple Sclerosis Journal*, **2004**, 10, 549-55	5	52
1024	MRI and CT in the diagnosis of vascular dementia. *Journal of the Neurological Sciences*, **2004**, 226, 9-12	3.2	52
1023	Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. *Neurology*, **2005**, 65, 633-5	6.5	52
1022	Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. *Neuroradiology*, **1999**, 41, 882-8	3.2	52
1021	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. *Neurobiology of Aging*, **2017**, 52, 167-182.e1	5.6	51
1020	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. *Stroke* , **2015**, 46, 2661-4	6.7	51
1019	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. *Journal of the Neurological Sciences*, **2011**, 307, 100-5	3.2	51
1018	Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. *Neuroimaging Clinics of North America*, **2009**, 19, 81-99	3	51

1017	Diffusion-weighted and conventional MR imaging in neonatal hypoxic ischemia: two-year follow-up study. *Radiology*, **2008**, 249, 631-9	20.5	51
1016	Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. *Neurology*, **2001**, 57, 2191-7	6.5	51
1015	Phase-contrast cine MR imaging of normal aqueductal CSF flow. *Acta Radiologica*, **1994**, 35, 123-130	2	51
1014	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. *JAMA Neurology*, **2015**, 72, 1433-41	17.2	50
1013	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. *Neurology*, **2018**, 90, e1183-e1190	6.5	50
1012	Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds, which is part of generalized microangiopathy. *Diabetes Care*, **2014**, 37, 1165-8	14.6	50
1011	Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. *European Radiology*, **2013**, 23, 528-40	8	50
1010	Resection probability maps for quality assessment of glioma surgery without brain location bias. *PLoS ONE*, **2013**, 8, e73353	3.7	50
1009	Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. *Neurology*, **2010**, 75, 1617-22	6.5	50
1008	Does high field MRI allow an earlier diagnosis of multiple sclerosis?. *Journal of Neurology*, **2008**, 255, 1159-63	5.5	50
1007	Diffusion-weighted MRI in severe neonatal hypoxic ischaemia: the white cerebrum. *Neuropediatrics*, **2003**, 34, 72-6	1.6	50
1006	Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. *Neurology*, **2019**, 92, 180-192	6.5	50
1005	Sex-specific extent and severity of white matter damage in multiple sclerosis: implications for cognitive decline. *Human Brain Mapping*, **2014**, 35, 2348-58	5.9	49
1004	Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1058-65	5	49
1003	Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. *Multiple Sclerosis Journal*, **2006**, 12, 760-8	5	49
1002	Assessment and correction of B1-induced errors in magnetization transfer ratio measurements. *Magnetic Resonance in Medicine*, **2005**, 53, 134-40	4.4	49
1001	Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. *American Journal of Neuroradiology*, **2006**, 27, 2005-11	4.4	49
1000	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. *Brain*, **2018**, 141, 3443-3456	11.2	49

999	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. *Lancet Neurology, The*, **2020**, 19, 214-225	24.1	48
998	Pathological aging of the brain: an overview. *Topics in Magnetic Resonance Imaging*, **2004**, 15, 369-89	2.3	48
997	Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. *Radiology*, **2013**, 269, 542-52	20.5	48
996	Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity. *Multiple Sclerosis Journal*, **2015**, 21, 1705-12	5	47
995	Structural MRI substrates of cognitive impairment in neuromyelitis optica. *Neurology*, **2015**, 85, 1491-9	6.5	47
994	Disrupted topological organization of structural and functional brain connectomes in clinically isolated syndrome and multiple sclerosis. *Scientific Reports*, **2016**, 6, 29383	4.9	47
993	Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. *Neurology*, **2019**, 93, e334-e346	6.5	47
992	Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. *Journal of Neurology*, **2013**, 260, 2016-22	5.5	47
991	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. *Journal of Alzheimeris Disease*, **2015**, 48, 711-20	4.3	47
990	Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis. *Human Brain Mapping*, **2015**, 36, 1796-807	5.9	47
989	Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. *Current Opinion in Neurology*, **2014**, 27, 260-70	7.1	47
988	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 882-4	5.5	47
987	Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. *Human Brain Mapping*, **2009**, 30, 2412-25	5.9	47
986	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. *Multiple Sclerosis Journal*, **2012**, 18, 1466-71	5	47
985	Small vessel versus large vessel vascular dementia: risk factors and MRI findings. *Journal of Neurology*, **2008**, 255, 1644-51; discussion 1813-4	5.5	47
984	Neurophysiological correlates of increased verbal working memory in high-dissociative participants: a functional MRI study. *Psychological Medicine*, **2005**, 35, 175-85	6.9	47
983	Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. *Neuroradiology*, **1994**, 36, 382-7	3.2	47
982	Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. *Annals of Neurology*, **1999**, 46, 79-87	9.4	47

981	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. *European Radiology*, **2014**, 24, 2326-33	8	46
980	Single-subject gray matter graph properties and their relationship with cognitive impairment in early- and late-onset Alzheimer's disease. *Brain Connectivity*, **2014**, 4, 337-46	2.7	46
979	Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 1011.e1-9	5.6	46
978	Fetal origin of brain damage in 2 infants with a COL4A1 mutation: fetal and neonatal MRI. *Neuropediatrics*, **2011**, 42, 1-3	1.6	46
977	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 455-64	5	46
976	Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. *Experimental Brain Research*, **2008**, 187, 25-31	2.3	46
975	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. *Alzheimeris and Dementia*, **2017**, 13, 1226-1236	1.2	45
974	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 908-916	5.5	45
973	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. *Lancet Neurology, The*, **2019**, 18, 1034-1044	24.1	45
972	Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes. *Diabetes Care*, **2016**, 39, 214-21	14.6	45
971	'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. *Developmental Medicine and Child Neurology*, **2018**, 60, 417-423	3.3	45
970	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. *Frontiers in Human Neuroscience*, **2015**, 9, 474	3.3	45
969	Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography. *PLoS ONE*, **2012**, 7, e42087	3.7	45
968	Segmentation of age-related white matter changes in a clinical multi-center study. *NeuroImage*, **2008**, 41, 335-45	7.9	45
967	Reproducibility of fMRI in the clinical setting: implications for trial designs. *NeuroImage*, **2008**, 42, 603-10	7.9	45
966	Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 70, 494-9	5.5	45
965	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. *Brain*, **2016**, 139, 2528-39	11.2	45
964	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [F]DPA714 PET. *Journal of Neuroinflammation*, **2018**, 15, 314	10.1	45

963	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. *Frontiers in Aging Neuroscience*, **2017**, 9, 117	5.3	44
962	The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. *Alzheimer Disease and Associated Disorders*, **1997**, 11, 63-70	2.5	44
961	Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. *Multiple Sclerosis Journal*, **2002**, 8, 415-9	5	44
960	CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. *Acta Neurologica Scandinavica*, **1992**, 86, 291-7	3.8	44
959	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. *Radiology*, **2016**, 281, 865-875	20.5	44
958	MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1138-45	5.5	44
957	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *Lancet Neurology, The*, **2021**, 20, 653-670	24.1	44
956	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 6, 143-151	5.2	43
955	Alterations in white matter volume and integrity in obesity and type 2 diabetes. *Metabolic Brain Disease*, **2016**, 31, 621-9	3.9	43
954	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. *Multiple Sclerosis and Related Disorders*, **2014**, 3, 147-55	4	43
953	MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. *Neurology*, **2009**, 72, 1693-701	6.5	43
952	White matter changes contribute to corpus callosum atrophy in the elderly: the LADIS study. *American Journal of Neuroradiology*, **2008**, 29, 1498-504	4.4	43
951	Global and regional differences in brain anatomy of young children born small for gestational age. *PLoS ONE*, **2011**, 6, e24116	3.7	43
950	Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. *Journal of Clinical Investigation*, **2019**, 129, 4758-4768	15.9	43
949	Imaging outcome measures for progressive multiple sclerosis trials. *Multiple Sclerosis Journal*, **2017**, 23, 1614-1626	5	42
948	Diffusion tensor imaging in type 1 diabetes: decreased white matter integrity relates to cognitive functions. *Diabetologia*, **2012**, 55, 1218-20	10.3	42
947	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. *Neurology*, **2013**, 80, 234-41	6.5	42
946	The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results. *BMC Neurology*, **2014**, 14, 254	3.1	42

945	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. *Neurology*, **2014**, 82, 1768-75	6.5	42
944	Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. *American Journal of Neuroradiology*, **2010**, 31, 541-8	4.4	42
943	CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. *Journal of Neuroimmunology*, **2007**, 190, 157-64	3.5	42
942	Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study. *Journal of Neurology*, **2002**, 249, 767-73	5.5	42
941	Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. *Multiple Sclerosis Journal*, **2002**, 8, 410-4	5	42
940	Increased connectivity of hub networks and cognitive impairment in multiple sclerosis. *Neurology*, **2017**, 88, 2107-2114	6.5	41
939	Inter-rater agreement in glioma segmentations on longitudinal MRI. *NeuroImage: Clinical*, **2019**, 22, 101727	3.3	41
938	Gray matter network disruptions and amyloid beta in cognitively normal adults. *Neurobiology of Aging*, **2016**, 37, 154-160	5.6	41
937	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. *Multiple Sclerosis Journal*, **2014**, 20, 1692-8	5	41
936	Early- and Late-Onset Depression in Late Life: A Prospective Study on Clinical and Structural Brain Characteristics and Response to Electroconvulsive Therapy. *American Journal of Geriatric Psychiatry*, **2017**, 25, 178-189	6.5	41
935	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study. *Journal of Alzheimeris Disease*, **2015**, 48, 197-204	4.3	41
934	Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration. *Journal of Magnetic Resonance Imaging*, **2012**, 36, 1-19	5.6	41
933	T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 72-7	5.5	41
932	Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. *Radiology*, **2009**, 250, 506-14	6.5	41
931	Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. *Archives of Neurology*, **2007**, 64, 1292-8		41
930	Thalamic lesions in vascular dementia: low sensitivity of fluid-attenuated inversion recovery (FLAIR) imaging. *Stroke*, **2004**, 35, 415-9	6.7	41
929	Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. *Neurology*, **2005**, 65, 56-61	6.5	41
928	Medial temporal lobe atrophy in an open population of very old persons: cognitive, brain atrophy, and sociomedical correlates. *Neurology*, **1995**, 45, 747-52	6.5	41

927	Connectomic profile and clinical phenotype in newly diagnosed glioma patients. *NeuroImage: Clinical*, **2017**, 14, 87-96	5.3	40
926	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 2340-7	5.6	40
925	MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 879-84	5.5	40
924	MRI mimics of multiple sclerosis. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2014**, 122, 291-316	3	40
923	Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation. *Obesity*, **2015**, 23, 2075-82	8	40
922	Widespread disruption of functional brain organization in early-onset Alzheimer's disease. *PLoS ONE*, **2014**, 9, e102995	3.7	40
921	Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement. *European Radiology*, **2011**, 21, 1526-34	8	40
920	Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. *Magnetic Resonance Imaging*, **1997**, 15, 155-62	3.3	40
919	Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. *Multiple Sclerosis Journal*, **2007**, 13, 708-16	5	40
918	White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. *Stroke*, **2006**, 37, 2248-52	6.7	40
917	Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. *Journal of Clinical Oncology*, **2003**, 21, 3559-65	2.2	40
916	Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. *Neurology*, **2005**, 65, 1447-54	6.5	40
915	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. *Human Brain Mapping*, **2017**, 38, 4703-4715	5.9	39
914	Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. *JAMA Neurology*, **2015**, 72, 539-45	17.2	39
913	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. *Neurology*, **2015**, 85, 1694-701	6.5	39
912	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. *Annals of Clinical and Translational Neurology*, **2014**, 1, 605-17	5.3	39
911	Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 774-9	5.6	39
910	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. *Journal of Magnetic Resonance Imaging*, **2007**, 26, 881-5	5.6	39

909	Isotropic 3D fast FLAIR imaging of the brain in multiple sclerosis patients: initial experience. *European Radiology*, **2002**, 12, 559-67	8	39
908	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. *Neurobiology of Aging*, **2013**, 34, 73-82	5.6	38
907	Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. *Psychiatry Research - Neuroimaging*, **2011**, 193, 182-90	2.9	38
906	Cerebrospinal fluid ATP metabolites in multiple sclerosis. *Multiple Sclerosis Journal*, **2010**, 16, 549-54	5	38
905	Two-year follow-up study of primary and transitional progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2002**, 8, 108-14	5	38
904	Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability **2000**, 10, 67-72		38
903	Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis. *European Radiology*, **2000**, 10, 753-8	8	38
902	Parametric fMRI analysis of visual encoding in the human medial temporal lobe. *Hippocampus*, **1999**, 9, 637-43	3.5	38
901	Head-to-head comparison of two popular cortical thickness extraction algorithms: a cross-sectional and longitudinal study. *PLoS ONE*, **2015**, 10, e0117692	3.7	38
900	Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues. *Diabetes Care*, **2017**, 40, 1522-1529	14.6	37
899	Randomized trial of daily high-dose vitamin D in patients with RRMS receiving subcutaneous interferon β1a. *Neurology*, **2019**, 93, e1906-e1916	6.5	37
898	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 383-391	5.2	37
897	Perivascular spaces in MS patients at 7 Tesla MRI: a marker of neurodegeneration?. *Multiple Sclerosis Journal*, **2015**, 21, 155-62	5	37
896	Interferon β1b-neutralizing antibodies 5 years after clinically isolated syndrome. *Neurology*, **2011**, 77, 835-43	6.5	37
895	CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. *Journal of Neuroimmunology*, **2003**, 140, 188-93	3.5	37
894	A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. *Annals of Neurology*, **2020**, 87, 63-74	9.4	37
893	Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. *Journal of Alzheimeris Disease*, **2016**, 53, 1287-97	4.3	37
892	More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer's disease. *Journal of Alzheimeris Disease*, **2015**, 44, 635-47	4.3	36

891	Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1176-7	5.5	36
890	The changing face of multiple sclerosis clinical trial populations. *Current Medical Research and Opinion*, **2011**, 27, 1529-37	2.5	36
889	Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. *Journal of Neurology, Neurosurgery and Psychiatry*, **2008**, 79, 917-23	5.5	36
888	Multislice T1 relaxation time measurements in the brain using IR-EPI: reproducibility, normal values, and histogram analysis in patients with multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2003**, 18, 656-64	5.6	36
887	Seasonal variation in immune measurements and MRI markers of disease activity in MS. *Neurology*, **2002**, 58, 1077-80	6.5	36
886	Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. *Brain*, **1998**, 121 (Pt 2), 225-31	11.2	36
885	Hippocampal sulcus width and cavities: comparison between patients with Alzheimer disease and nondemented elderly subjects. *American Journal of Neuroradiology*, **2006**, 27, 2141-5	4.4	36
884	Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. *JAMA Neurology*, **2021**,	17.2	36
883	White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients. *Journal of Clinical Psychiatry*, **2011** , 72, 104-12	4.6	36
882	Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. *Journal of Endocrinology*, **2016**, 229, 1-12	4.7	35
881	Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. *American Journal of Neuroradiology*, **2017**, 38, 1884-1891	4.4	35
880	New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. *Dementia and Geriatric Cognitive Disorders*, **2010**, 30, 1-7	2.6	35
879	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. *Alzheimeris and Dementia*, **2008**, 4, 255-64	1.2	35
878	Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. *Neuropsychopharmacology*, **2006**, 31, 1508-18	8.7	35
877	Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. *NeuroImage*, **2007**, 34, 1036-41	7.9	35
876	Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. *Multiple Sclerosis Journal*, **2003**, 9, 342-8	5	35
875	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. *Journal of Neuro-Oncology*, **2017**, 132, 255-266	4.8	34
874	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1704-13	5	34

873	Improvement of white matter changes on neuroimaging modalities after stem cell transplant in metachromatic leukodystrophy. *JAMA Neurology*, **2013**, 70, 779-82	17.2	34
872	Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. *CardioVascular and Interventional Radiology*, **2011**, 34, 1-2	2.7	34
871	Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. *Multiple Sclerosis Journal*, **2010**, 16, 660-9	5	34
870	Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 764-9	5	34
869	Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. *NeuroImage*, **2007**, 38, 529-37	7.9	34
868	Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. *Journal of Neuroimmunology*, **2002**, 133, 225-32	3.5	34
867	rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 386-394	5.5	33
866	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. *NeuroImage: Clinical*, **2018**, 19, 466-475	5.3	33
865	Translating pathology in multiple sclerosis: the combination of postmortem imaging, histopathology and clinical findings. *Acta Neurologica Scandinavica*, **2009**, 119, 349-55	3.8	33
864	Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis. *NeuroImage*, **2009**, 45, 500-11	7.9	33
863	Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study. *Dementia and Geriatric Cognitive Disorders*, **2007**, 24, 73-81	2.6	33
862	Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. *Clinical Neurophysiology*, **2007**, 118, 1332-40	4.3	33
861	Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. *NeuroImage*, **2005**, 25, 63-75	7.9	33
860	Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method. *PLoS ONE*, **2016**, 11, e0143942	3.7	33
859	Assessing Amyloid Pathology in Cognitively Normal Subjects Using F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. *Journal of Nuclear Medicine*, **2019**, 60, 541-547	8.9	33
858	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. *Human Brain Mapping*, **2016**, 37, 978-88	5.9	32
857	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2016**, 38, 21-31	5.6	32
856	Applying the ATN scheme in a memory clinic population: The ABIDE project. *Neurology*, **2019**, 93, e1635-e1646	6.5	32

855	Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. *NeuroImage: Clinical*, **2014**, 4, 366-73	5.3	32
854	Grid infrastructures for computational neuroscience: the neuGRID example. *Future Neurology*, **2009**, 4, 703-722	1.5	32
853	White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 1069-74	5.5	32
852	The distribution of new enhancing lesion counts in multiple sclerosis: further explorations. *Multiple Sclerosis Journal*, **2009**, 15, 42-9	5	32
851	The role of MRI as a surrogate outcome measure in multiple sclerosis. *Multiple Sclerosis Journal*, **2002**, 8, 40-51	5	32
850	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. *Nature Communications*, **2021**, 12, 2078	17.4	32
849	Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. *Neurology*, **2015**, 85, 248-55	6.5	31
848	7T T□-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 20-6	5.6	31
847	Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 608-19	5	31
846	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. *Alzheimeris Research and Therapy*, **2018**, 10, 64	9	31
845	Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. *Diabetologia*, **2014**, 57, 2208-14	10.3	31
844	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. *Human Brain Mapping*, **2015**, 36, 3516-27	5.9	31
843	Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects. *Human Brain Mapping*, **2012**, 33, 1225-45	5.9	31
842	Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. *Journal of Alzheimeris Disease*, **2012**, 29, 459-69	4.3	31
841	MR imaging in retinoblastoma. *European Radiology*, **1997**, 7, 726-31	8	31
840	Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. *Annals of Oncology*, **2007**, 18, 1747-50	10.3	31
839	Progression of cerebral white matter lesions in Alzheimer's disease: a new window for therapy?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1286-8	5.5	31
838	Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. *Journal of Neuroimmunology*, **2003**, 142, 141-8	3.5	31

837	Interindividual differences of medial temporal lobe activation during encoding in an elderly population studied by fMRI. *NeuroImage*, **2004**, 21, 173-80	7.9	31
836	Raloxifene affects brain activation patterns in postmenopausal women during visual encoding. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 1422-4	5.6	31
835	Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1296-1302	5.5	31
834	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. *Journal of Alzheimeris Disease*, **2017**, 55, 521-537	4.3	31
833	Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. *Journal of Alzheimeris Disease*, **2017**, 57, 557-573	4.3	30
832	Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica. *Radiology*, **2015**, 277, 784-92	20.5	30
831	ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. *Neurology*, **2020**, 95, e46-e58	6.5	30
830	Morphological features of MS lesions on FLAIR* at 7□T and their relation to patient characteristics. *Journal of Neurology*, **2014**, 261, 1356-64	5.5	30
829	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: the LADIS (Leukoaraiosis and Disability in the Elderly) study. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 268-74	5.6	30
828	Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 64, 50-5	5.5	30
827	The P2X receptor tracer [C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 379-389	8.8	30
826	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2016**, 5, 43-52	5.2	30
825	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. *Alzheimeris Research and Therapy*, **2018**, 10, 100	9	30
824	Clinical phenotype, atrophy, and small vessel disease in □ carriers with Alzheimer disease. *Neurology*, **2018**, 91, e1851-e1859	6.5	30
823	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. *Neurobiology of Aging*, **2018**, 61, 75-81	5.6	29
822	Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study. *Multiple Sclerosis Journal*, **2016**, 22, 901-9	5	29
821	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 9, 76-83	5.2	29
820	Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. *Multiple Sclerosis Journal*, **2017**, 23, 656-664	5	29

819	Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. *Neurology*, **2010**, 75, 1228-33	6.5	29
818	Association between MRI parameters and the MS severity scale: a 12 year follow-up study. *Multiple Sclerosis Journal*, **2009**, 15, 632-7	5	29
817	N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. *Journal of Neurology*, **2007**, 254, 631-7	5.5	29
816	No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. *Multiple Sclerosis Journal*, **2004**, 10, 272-7	5	29
815	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. *Brain*, **2020**, 143, 2831-2843	11.2	29
814	T1 hypointensities and axonal loss. *Neuroimaging Clinics of North America*, **2000**, 10, 739-52 ,ix	3	29
813	Long-term motor and behavioral outcome after perinatal hypoxic-ischemic encephalopathy. *European Journal of Paediatric Neurology*, **2015**, 19, 354-9	3.8	28
812	Linking late cognitive outcome with glioma surgery location using resection cavity maps. *Human Brain Mapping*, **2018**, 39, 2064-2074	5.9	28
811	Amyloid and its association with default network integrity in Alzheimer's disease. *Human Brain Mapping*, **2014**, 35, 779-91	5.9	28
810	Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. *Archives of Neurology*, **2009**, 66, 1345-52		28
809	The FAS-670 polymorphism influences susceptibility to multiple sclerosis. *Journal of Neuroimmunology*, **2002**, 128, 95-100	3.5	28
808	Magnetic source imaging contributes to the presurgical identification of sensorimotor cortex in patients with frontal lobe epilepsy. *Clinical Neurophysiology*, **2003**, 114, 221-32	4.3	28
807	Evidence for atrophy of the corpus callosum in Alzheimer's disease. *European Neurology*, **1994**, 34, 83-6	2.1	28
806	Sagittal MR of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging. *American Journal of Neuroradiology*, **1998**, 19, 355-60	4.4	28
805	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. *Human Brain Mapping*, **2016**, 37, 2114-32	5.9	27
804	High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 1279-88	5	27
803	Correlating quantitative MR imaging with histopathology in X-linked adrenoleukodystrophy. *American Journal of Neuroradiology*, **2011**, 32, 481-9	4.4	27
802	Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. *Neuroradiology*, **2010**, 52, 875-81	3.2	27

801	Whole brain analysis of T2* weighted baseline FMRI signal in dementia. *Human Brain Mapping*, **2007**, 28, 1313-7	5.9	27
800	Infratentorial abnormalities in vascular dementia. *Stroke*, **2006**, 37, 105-10	6.7	27
799	Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. *American Journal of Neuroradiology*, **1997**, 18, 1279-85	4.4	27
798	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. *Frontiers in Aging Neuroscience*, **2018**, 10, 279	5.3	27
797	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. *Alzheimeris Research and Therapy*, **2018**, 10, 112	9	27
796	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. *Alzheimeris and Dementia*, **2019**, 15, 817-827	1.2	26
795	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. *Human Brain Mapping*, **2018**, 39, 3143-3151	5.9	26
794	Ventral striatum, but not cortical volume loss, is related to cognitive dysfunction in type 1 diabetic patients with and without microangiopathy. *Diabetes Care*, **2014**, 37, 2483-90	14.6	26
793	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. *NeuroImage: Clinical*, **2015**, 9, 418-29	5.3	26
792	Quantification of cerebral blood flow in healthy volunteers and type 1 diabetic patients: comparison of MRI arterial spin labeling and [(15)O]H2O positron emission tomography (PET). *Journal of Magnetic Resonance Imaging*, **2014**, 40, 1300-9	5.6	26
791	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. *Multiple Sclerosis Journal*, **2009**, 15, 1459-65	5	26
790	The predictive value of 3D time-of-flight MR angiography in assessment of brain arteriovenous malformation obliteration after radiosurgery. *American Journal of Neuroradiology*, **2012**, 33, 232-8	4.4	26
789	HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. *Archives of Neurology*, **2009**, 66, 1531-6		26
788	Modelling new enhancing MRI lesion counts in multiple sclerosis. *Multiple Sclerosis Journal*, **2001**, 7, 298-304	3	26
787	Serial isotropic three-dimensional fast FLAIR imaging: using image registration and subtraction to reveal active multiple sclerosis lesions. *American Journal of Roentgenology*, **2002**, 179, 777-82	5.4	26
786	Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study. *European Neurology*, **1998**, 40, 91-8	2.1	26
785	The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis. *Journal of Neuroimmunology*, **1992**, 40, 265-72	3.5	26
784	Bacillus cereus meningoencephalitis in preterm infants: neuroimaging characteristics. *American Journal of Neuroradiology*, **2005**, 26, 2137-43	4.4	26

783	Impact of APOE-e4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. *Neurobiology of Aging*, **2016**, 38, 14-20	5.6	26
782	Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 476-488	5	26
781	Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm. *Annals of Neurology*, **2020**, 88, 93-105	9.4	26
780	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. *BMJ Open*, **2018**, 8, e021944	3	26
779	Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. *Neuroradiology*, **2019**, 61, 633-642	3.2	25
778	ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies. *NeuroImage*, **2020**, 219, 117031	7.9	25
777	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. *Neurobiology of Aging*, **2018**, 61, 198-206	5.6	25
776	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. *Alzheimeris Research and Therapy*, **2018**, 10, 72	9	25
775	and cortical superficial siderosis in CAA: Meta-analysis and potential mechanisms. *Neurology*, **2019**, 93, e358-e371	6.5	25
774	Differentiation of edema and glioma infiltration: proposal of a DTI-based probability map. *Journal of Neuro-Oncology*, **2014**, 120, 187-98	4.8	25
773	Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?. *Journal of Neurology*, **2014**, 261, 1139-43	5.5	25
772	Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study. *NeuroImage: Clinical*, **2013**, 2, 727-34	5.3	25
771	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. *European Radiology*, **2014**, 24, 397-404	8	25
770	MRI--the perfect surrogate marker for multiple sclerosis?. *Nature Reviews Neurology*, **2009**, 5, 182-3	15	25
769	Unraveling pathology in juvenile Alexander disease: serial quantitative MR imaging and spectroscopy of white matter. *Neuroradiology*, **2009**, 51, 669-75	3.2	25
768	Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy. *Neurology*, **2011**, 76, S28-37	6.5	25
767	Segmentation of subtraction images for the measurement of lesion change in multiple sclerosis. *American Journal of Neuroradiology*, **2008**, 29, 340-6	4.4	25
766	Voxel-based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter. *American Journal of Neuroradiology*, **2006**, 27, 868-74	4.4	25

765	APOE ε4 status is associated with white matter hyperintensities volume accumulation rate independent of AD diagnosis. *Neurobiology of Aging*, **2017**, 53, 67-75	5.6	24
764	Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. *Alzheimeris Research and Therapy*, **2019**, 11, 12	9	24
763	Lifespan normative data on rates of brain volume changes. *Neurobiology of Aging*, **2019**, 81, 30-37	5.6	24
762	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. *Alzheimeris and Dementia*, **2014**, 10, S299-305	1.2	24
761	Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. *Neurobiology of Aging*, **2013**, 34, 238-47	5.6	24
760	An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. *American Journal of Neuroradiology*, **2013**, 34, 1550-5	4.4	24
759	Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 202-13	5	24
758	Characteristics of early MRI in children and adolescents with vanishing white matter. *Neuropediatrics*, **2012**, 43, 22-6	1.6	24
757	Structural neuroimaging58-69		24
756	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. *International Journal of Geriatric Psychiatry*, **2008**, 23, 387-92	3.9	24
755	Visual rating of hippocampal atrophy: correlation with volumetry. *Journal of Neurology, Neurosurgery and Psychiatry*, **1994**, 57, 1015	5.5	24
754	Predicting clinical progression in multiple sclerosis after 6 and 12 years. *European Journal of Neurology*, **2019**, 26, 893-902	6	24
753	Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. *Neuro-Oncology*, **2020**, 22, 412-422	1	24
752	The EMIF-AD PreclinAD study: study design and baseline cohort overview. *Alzheimeris Research and Therapy*, **2018**, 10, 75	9	24
751	Subcutaneous interferon β1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 285-294	5.5	23
750	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE-e4 Homozygosity. *Journal of Alzheimeris Disease*, **2017**, 56, 63-74	4.3	23
749	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. *NeuroImage: Clinical*, **2017**, 15, 613-624	5.3	23
748	Disrupted white matter structural networks in healthy older adult APOE ε4 carriers - An international multicenter DTI study. *Neuroscience*, **2017**, 357, 119-133	3.9	23

747	Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. *European Radiology*, **2017**, 27, 4237-4246	8	23
746	Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. *Neurology*, **2019**, 93, e1348-e1359	8.5	23
745	SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis. *NeuroImage: Clinical*, **2019**, 24, 102011	5.3	23
744	White matter hyperintensities and cognitive impairment during electroconvulsive therapy in severely depressed elderly patients. *American Journal of Geriatric Psychiatry*, **2014**, 22, 157-66	6.5	23
743	Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 106-12	5.5	23
742	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 2665-2670	5.6	23
741	Cortical imaging in multiple sclerosis: recent findings and 'grand challenges'. *Current Opinion in Neurology*, **2013**, 26, 345-52	7.1	23
740	Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings. *Alzheimer Disease and Associated Disorders*, **2010**, 24, 303-7	2.5	23
739	Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. *Acta Neurologica Scandinavica*, **1994**, 90, 105-10	3.8	23
738	Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. *Archives of Neurology*, **2007**, 64, 190-4		23
737	Postmortem validation of MRI cortical volume measurements in MS. *Human Brain Mapping*, **2016**, 37, 2223-33	5.9	23
736	Altered eigenvector centrality is related to local resting-state network functional connectivity in patients with longstanding type 1 diabetes mellitus. *Human Brain Mapping*, **2017**, 38, 3623-3636	5.9	22
735	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. *Neurology*, **2019**, 93, e1778-e1786	6.5	22
734	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. *Alzheimeris and Dementia*, **2019**, 15, 1478-1488	1.2	22
733	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. *Alzheimeris Research and Therapy*, **2019**, 11, 33	9	22
732	Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. *Journal of Alzheimeris Disease*, **2018**, 62, 1827-1839	4.3	22
731	Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis. *American Journal of Neuroradiology*, **2016**, 37, 749-54	4.4	22
730	Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. *Annals of Neurology*, **2019**, 86, 704-713	9.4	22

729	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. *Neurology*, **2019**, 93, e1852-e1866	6.5	22
728	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. *Multiple Sclerosis Journal*, **2014**, 20, 1471-7	5	22
727	Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 1605.e13-20	5.6	22
726	Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. *American Journal of Geriatric Psychiatry*, **2014**, 22, 735-40	6.5	22
725	Leucoencephalopathy with brainstem and spinal cord involvement and high lactate: quantitative magnetic resonance imaging. *Brain*, **2011**, 134, 3333-41	11.2	22
724	Quantitative MR imaging and spectroscopy in congenital cytomegalovirus infection and periventricular leukomalacia suggests a comparable neuropathological substrate of the cerebral white matter lesions. *Neuropediatrics*, **2009**, 40, 168-73	1.6	22
723	Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. *Annals of Neurology*, **2010**, 67, 667-75	9.4	22
722	Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. *Annals of the New York Academy of Sciences*, **2007**, 1097, 215-24	6.5	22
721	Is the whole brain periventricular?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 143-4	5.5	22
720	Asymptomatic carotid artery stenosis: past, present and future. How to improve patient selection?. *European Neurology*, **2006**, 56, 139-54	2.1	22
719	Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. *European Neurology*, **2007**, 58, 90-5	2.1	22
718	Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. *Annals of Neurology*, **2002**, 51, 467-74	9.4	22
717	Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: atypical molecular phenotype. *Annals of Neurology*, **2001**, 50, 258-61	9.4	22
716	Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells. *Journal of Neuroimmunology*, **2001**, 118, 286-94	3.5	22
715	A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. *Multiple Sclerosis Journal*, **1996**, 1, 339-42	5	22
714	Detecting frontotemporal dementia syndromes using MRI biomarkers. *NeuroImage: Clinical*, **2019**, 22, 101711	5.3	21
713	Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. *Dementia and Geriatric Cognitive Disorders*, **2016**, 41, 210-9	2.6	21
712	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. *Frontiers in Aging Neuroscience*, **2018**, 10, 111	5.3	21

711	Inflammation high-field magnetic resonance imaging. *Neuroimaging Clinics of North America*, **2012**, 22, 135-57, ix	3	21
710	A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. *European Journal of Neuroscience*, **2011**, 33, 1256-63	3.5	21
709	Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. *Neurology*, **2011**, 76, 574-6	6.5	21
708	Preliminary evidence of hippocampal damage in chronic users of ecstasy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 83-5	5.5	21
707	Spinal cord magnetic resonance imaging in suspected multiple sclerosis. *European Radiology*, **2000**, 10, 368-76	8	21
706	Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone. *Journal of Neurology*, **1993**, 240, 305-8	5.5	21
705	Gray matter networks and cognitive impairment in multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 382-391	5	21
704	Comparing Glioblastoma Surgery Decisions Between Teams Using Brain Maps of Tumor Locations, Biopsies, and Resections. *JCO Clinical Cancer Informatics*, **2019**, 3, 1-12	5.2	20
703	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. *Alzheimeris Research and Therapy*, **2017**, 9, 73	9	20
702	Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. *Neurology*, **2018**, 91, e1130-e1134	6.5	20
701	The structure of the geriatric depressed brain and response to electroconvulsive therapy. *Psychiatry Research - Neuroimaging*, **2014**, 222, 1-9	2.9	20
700	Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy. *NeuroImage: Clinical*, **2017**, 15, 843-853	5.3	20
699	Corpus callosum tissue loss and development of motor and global cognitive impairment: the LADIS study. *Dementia and Geriatric Cognitive Disorders*, **2011**, 32, 279-86	2.6	20
698	Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2012**, 18, 1577-84	5	20
697	Determination of individual stimulus--response curves in the visual cortex. *Human Brain Mapping*, **2002**, 17, 244-50	5.9	20
696	[Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype. *Neurology*, **2003**, 61, 1245-9	6.5	20
695	Detection of root avulsion in the dominant C7 obstetric brachial plexus lesion: experience with three-dimensional constructive interference in steady-state magnetic resonance imaging and electrophysiology. *Neurosurgery*, **2005**, 57, 930-40; discussion 930-40	3.2	20
694	Multitracer model for staging cortical amyloid deposition using PET imaging. *Neurology*, **2020**, 95, e1538-e1553	6.5	20

693	Sex differences in CSF biomarkers vary by Alzheimer disease stage and ε4 genotype. *Neurology*, **2020**, 95, e2378-e2388	6.5	20
692	Novel MRI and PET markers of neuroinflammation in multiple sclerosis. *Current Opinion in Neurology*, **2016**, 29, 229-36	7.1	20
691	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. *Scientific Reports*, **2019**, 9, 16742	4.9	20
690	Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. *Human Brain Mapping*, **2016**, 37, 1194-208	5.9	19
689	Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. *Multiple Sclerosis Journal*, **2016**, 22, 1174-83	5	19
688	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 24, 101954	5.3	19
687	Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. *Journal of Alzheimeris Disease*, **2013**, 36, 79-85	4.3	19
686	Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials. *Multiple Sclerosis Journal*, **1997**, 2, 283-90	5	19
685	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. *Neuropathology and Applied Neurobiology*, **2006**, 32, 318-31	5.2	19
684	Low vitamin B6 levels are associated with white matter lesions in Alzheimer's disease. *Journal of the American Geriatrics Society*, **2005**, 53, 1073-4	5.6	19
683	Blood pressure, white matter lesions and medial temporal lobe atrophy: closing the gap between vascular pathology and Alzheimer's disease?. *Dementia and Geriatric Cognitive Disorders*, **2005**, 20, 331-7	2.6	19
682	The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. *Multiple Sclerosis Journal*, **2000**, 6, 237-40	5	19
681	AMYPAD Diagnostic and Patient Management Study: Rationale and design. *Alzheimeris and Dementia*, **2019**, 15, 388-399	1.2	19
680	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies. *Alzheimeris and Dementia*, **2019**, 15, 185-193	1.2	19
679	Bullseye's representation of cerebral white matter hyperintensities. *Journal of Neuroradiology*, **2018**, 45, 114-122	3.1	19
678	Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 535-541	5.5	19
677	Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study. *Journal of Neurology*, **2015**, 262, 1074-80	5.5	18
676	Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. *JAMA Neurology*, **2018**, 75, 827-833	17.2	18

675	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. *Neurobiology of Aging*, **2018**, 61, 238-244	5.6	18
674	Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 1306-14	5	18
673	Disrupted Module Efficiency of Structural and Functional Brain Connectomes in Clinically Isolated Syndrome and Multiple Sclerosis. *Frontiers in Human Neuroscience*, **2018**, 12, 138	3.3	18
672	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. *Frontiers in Aging Neuroscience*, **2018**, 10, 67	5.3	18
671	Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study. *Neurology*, **2018**, 91, e249-e257	6.5	18
670	Associations between quantitative [F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum. *Alzheimeris Research and Therapy*, **2019**, 11, 60	9	18
669	Validation of the automated method VIENA: an accurate, precise, and robust measure of ventricular enlargement. *Human Brain Mapping*, **2014**, 35, 1101-10	5.9	18
668	Changes in MEG resting-state networks are related to cognitive decline in type 1 diabetes mellitus patients. *NeuroImage: Clinical*, **2014**, 5, 69-76	5.3	18
667	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 281-8	5	18
666	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. *NeuroImage*, **2017**, 163, 106-114	7.9	18
665	Longitudinal absolute metabolite quantification of white and gray matter regions in healthy controls using proton MR spectroscopic imaging. *NMR in Biomedicine*, **2014**, 27, 304-11	4.4	18
664	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. *BMC Neuroscience*, **2012**, 13, 85	3.2	18
663	Associations between magnetic resonance imaging measures and neuropsychological impairment in early and late onset alzheimer's disease. *Journal of Alzheimeris Disease*, **2013**, 35, 169-78	4.3	18
662	Diffusion magnetic resonance imaging in multiple sclerosis. *Neuroimaging Clinics of North America*, **2011**, 21, 71-88, vii-viii	3	18
661	Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. *Alzheimer Disease and Associated Disorders*, **2010**, 24, 242-7	2.5	18
660	Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. *Journal of Magnetic Resonance Imaging*, **2008**, 28, 559-65	5.6	18
659	Motor outcome at the age of one after perinatal hypoxic-ischemic encephalopathy. *Neuropediatrics*, **2007**, 38, 71-7	1.6	18
658	The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. *Multiple Sclerosis Journal*, **2003**, 9, 535-9	5	18

657	TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS. *Neurology*, **2001**, 57, 1129-31	6.5	18
656	Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. *Psychiatry Research - Neuroimaging*, **2016**, 252, 26-35	2.9	18
655	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. *Nature Reviews Neurology*, **2021**, 17, 173-184	15	18
654	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. *NeuroImage: Clinical*, **2018**, 19, 625-632	5.3	18
653	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. *Multiple Sclerosis Journal*, **2017**, 23, 1909-1917	5	17
652	Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. *European Radiology*, **2019**, 29, 4670-4677	8	17
651	Disturbed phase relations in white matter hyperintensity based vascular dementia: an EEG directed connectivity study. *Clinical Neurophysiology*, **2015**, 126, 497-504	4.3	17
650	Progressive brain rich-club network disruption from clinically isolated syndrome towards multiple sclerosis. *NeuroImage: Clinical*, **2018**, 19, 232-239	5.3	17
649	The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. *Alzheimeris Research and Therapy*, **2014**, 6, 47	9	17
648	Callosal tissue loss parallels subtle decline in psychomotor speed. a longitudinal quantitative MRI study. The LADIS Study. *Neuropsychologia*, **2012**, 50, 1650-5	3.2	17
647	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. *Multiple Sclerosis Journal*, **2014**, 20, 234-42	5	17
646	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 1145-8	5.5	17
645	Coil-treated aneurysms: decision making regarding additional treatment based on findings of MR angiography and intraarterial DSA. *Radiology*, **2012**, 265, 858-63	20.5	17
644	Novel hypomyelinating leukoencephalopathy affecting early myelinating structures. *Archives of Neurology*, **2012**, 69, 125-8		17
643	Imaging of remyelination. *Multiple Sclerosis Journal*, **1997**, 3, 129-32	5	17
642	Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS. *Journal of Neuroimmunology*, **2007**, 186, 150-5	3.5	17
641	Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. *Journal of Neurology, Neurosurgery and Psychiatry*, **1999**, 66, 465-9	5.5	17
640	Interobserver agreement for diagnostic MRI criteria in suspected multiple sclerosis. *Neuroradiology*, **1999**, 41, 347-50	3.2	17

639	Partially saturated fluid attenuated inversion recovery (FLAIR) sequences in multiple sclerosis: comparison with fully relaxed FLAIR and conventional spin-echo. *Magnetic Resonance Imaging*, **1995**, 13, 513-21	3.3	17
638	Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. *Neurology*, **2020**, 95, e745-e754	6.5	17
637	PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. *Alzheimeris Research and Therapy*, **2019**, 11, 100	9	17
636	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. *Brain Imaging and Behavior*, **2020**, 14, 2012-2023	4.1	17
635	Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. *European Radiology*, **2018**, 28, 96-103	8	16
634	Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 44-46	5.5	16
633	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. *Neurobiology of Aging*, **2019**, 84, 225-234	5.6	16
632	Early-Stage White Matter Lesions Detected by Multispectral MRI Segmentation Predict Progressive Cognitive Decline. *Frontiers in Neuroscience*, **2015**, 9, 455	5.1	16
631	Efficacy of subcutaneous interferon β1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 647-53	5.5	16
630	Delineation of brain AVMs on MR-Angiography for the purpose of stereotactic radiosurgery. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 308-16	4	16
629	Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis. *International Journal of Immunogenetics*, **2004**, 31, 133-40		16
628	The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. *Journal of Neuroimmunology*, **2003**, 138, 123-31	3.5	16
627	The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement. *Journal of Neurology*, **2000**, 247, 34-40	5.5	16
626	Multiple sclerosis therapy. A practical guide. *Drugs*, **1995**, 49, 200-12	12.1	16
625	Cerebral white matter abnormalities in 6p25 deletion syndrome. *American Journal of Neuroradiology*, **2006**, 27, 586-8	4.4	16
624	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. *Brain*, **2020**, 143, 3776-3792	11.2	16
623	Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods. *European Radiology*, **2020**, 30, 1062-1074	8	16
622	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. *Alzheimeris and Dementia*, **2020**, 16, 1457-1468	1.2	16

621	Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications. *Radiology*, **2021**, 299, 3-26	20.5	16
620	Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. *Multiple Sclerosis Journal*, **2020**, 26, 1372-1380	5	16
619	The European DTI Study on Dementia - A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. *NeuroImage*, **2017**, 144, 305-308	7.9	15
618	Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis. *American Journal of Neuroradiology*, **2015**, 36, 1116-23	4.4	15
617	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. *NeuroImage*, **2020**, 218, 116932	7.9	15
616	Cortical and subcortical gray matter structural alterations in normoglycemic obese and type 2 diabetes patients: relationship with adiposity, glucose, and insulin. *Metabolic Brain Disease*, **2018**, 33, 1211-1222	3.9	15
615	Cerebral rituximab uptake in multiple sclerosis: A Zr-immunoPET pilot study. *Multiple Sclerosis Journal*, **2018**, 24, 543-545	5	15
614	Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study): A Diagnostic Study Protocol. *Neurosurgery*, **2016**, 79, 535-40	3.2	15
613	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. *Journal of Psychiatric Research*, **2018**, 104, 183-191	5.2	15
612	Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 463-471	5.2	15
611	MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. *BMC Neurology*, **2009**, 9, 19	3.1	15
610	Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis. *Multiple Sclerosis Journal*, **1997**, 3, 226-30	5	15
609	Pre-and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease. *Journal of the Neurological Sciences*, **1993**, 117, 175-8	3.2	15
608	Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging. *Neuroradiology*, **1991**, 33, 70-1	3.2	15
607	In vivo tau pathology is associated with synaptic loss and altered synaptic function. *Alzheimeris Research and Therapy*, **2021**, 13, 35	9	15
606	A novel partial volume correction method for accurate quantification of [F] flortaucipir in the hippocampus. *EJNMMI Research*, **2018**, 8, 79	3.6	15
605	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. *BMC Geriatrics*, **2018**, 18, 289	4.1	15
604	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. *Brain Connectivity*, **2016**, 6, 1-8	2.7	14

603	Cortical cerebral blood flow in ageing: effects of haematocrit, sex, ethnicity and diabetes. *European Radiology*, **2019**, 29, 5549-5558	8	14
602	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. *Neurology*, **2019**, 92, e1558-e1566	6.5	14
601	Brain atrophy measurements should be used to guide therapy monitoring in MS - NO. *Multiple Sclerosis Journal*, **2016**, 22, 1524-1526	5	14
600	Association between tumor location and neurocognitive functioning using tumor localization maps. *Journal of Neuro-Oncology*, **2019**, 144, 573-582	4.8	14
599	Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). *Multiple Sclerosis and Related Disorders*, **2014**, 3, 355-63	4	14
598	Volumetric MRI data correlate to disease severity in metachromatic leukodystrophy. *Annals of Clinical and Translational Neurology*, **2015**, 2, 932-40	5.3	14
597	Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?. *Multiple Sclerosis Journal*, **2014**, 20, 1131-4	5	14
596	T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone. *Acta Neurologica Scandinavica*, **1993**, 88, 80-6	3.8	14
595	Restricted diffusion in vanishing white matter. *Archives of Neurology*, **2012**, 69, 723-7		14
594	Oral or intravenous methylprednisolone for acute relapses of MS?. *Lancet, The*, **1997**, 349, 893-4	40	14
593	Diagnostic tools for the study of vascular cognitive dysfunction in hypertension and antihypertensive drug research **2006**, 109, 274-83		14
592	Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. *Journal of Neuroimmunology*, **2005**, 158, 222-30	3.5	14
591	TADPOLE Challenge: Accurate Alzheimer's disease prediction through crowdsourced forecasting of future data. *Lecture Notes in Computer Science*, **2019**, 11843, 1-10	0.9	14
590	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. *Brain Imaging and Behavior*, **2019**, 13, 1361-1374	4.1	14
589	Cardiovascular Risk Factors and White Matter Hyperintensities: Difference in Susceptibility in South Asians Compared With Europeans. *Journal of the American Heart Association*, **2018**, 7, e010533	6	14
588	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 997-1004	5.5	13
587	Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 11020-11027	11.5	13
586	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 22, 101786	5.3	13

585	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. *Alzheimeris Research and Therapy*, **2018**, 10, 23	9	13
584	Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 491-500	5	13
583	Multi-scale MRI spectrum detects differences in myelin integrity between MS lesion types. *Multiple Sclerosis Journal*, **2016**, 22, 1569-1577	5	13
582	Multicenter R2* mapping in the healthy brain. *Magnetic Resonance in Medicine*, **2014**, 71, 1103-7	4.4	13
581	2010 revisions to McDonald criteria for diagnosis of multiple sclerosis: impact of 3-Tesla magnetic resonance imaging. *Annals of Neurology*, **2011**, 70, 182-3	9.4	13
580	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. *Multiple Sclerosis Journal*, **2009**, 15, 465-71	5	13
579	White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. *Human Brain Mapping*, **2020**, 41, 1309-1322	5.9	13
578	Pathologic correlates of the magnetization transfer ratio in multiple sclerosis. *Neurology*, **2020**, 95, e2965-e2976	5.5	13
577	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. *Multiple Sclerosis Journal*, **2021**, 13524585211024997	5	13
576	Comparing lesion segmentation methods in multiple sclerosis: Input from one manually delineated subject is sufficient for accurate lesion segmentation. *NeuroImage: Clinical*, **2019**, 24, 102074	5.3	13
575	Diagnostic criteria for primary progressive multiple sclerosis: A position paper **2000**, 47, 831		13
574	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. *Movement Disorders*, **2020**, 35, 859-867	7	13
573	4H Leukodystrophy: A Brain Magnetic Resonance Imaging Scoring System. *Neuropediatrics*, **2017**, 48, 152-160	1.6	12
572	Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. *Alzheimeris and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 157-165	6	12
571	The Meta VCI Map consortium for meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping: Design and multicenter pilot study. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 310-326	5.2	12
570	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. *Lecture Notes in Computer Science*, **2016**, 87-96	0.9	12
569	Evaluating combinations of diagnostic tests to discriminate different dementia types. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 509-518	5.2	12
568	The quantitative neuroradiology initiative framework: application to dementia. *British Journal of Radiology*, **2019**, 92, 20190365	3.4	12

567	Head motion parameters in fMRI differ between patients with mild cognitive impairment and Alzheimer disease versus elderly control subjects. *Brain Topography*, **2014**, 27, 801-7	4.3	12
566	The SIENA/FSL whole brain atrophy algorithm is no more reproducible at 3T than 1.5 T for Alzheimer's disease. *Psychiatry Research - Neuroimaging*, **2014**, 224, 14-21	2.9	12
565	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. *Journal of Alzheimeris Disease*, **2016**, 50, 261-70	4.3	12
564	Patient subgroup analyses of the treatment effect of subcutaneous interferon β1a on development of multiple sclerosis in the randomized controlled REFLEX study. *Journal of Neurology* , **2014**, 261, 490-9	5.5	12
563	Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. *Multiple Sclerosis Journal*, **2010**, 16, 325-31	5	12
562	One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1125-31	5.5	12
561	Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. *Multiple Sclerosis Journal*, **2012**, 18, 1092-8	5	12
560	Prenatal diagnosis of aneurysms of the vein of Galen (vena magna cerebri) with conventional sonography, three-dimensional sonography, and magnetic resonance imaging: report of 2 cases. *Journal of Ultrasound in Medicine*, **2003**, 22, 1363-8	2.9	12
559	Differences between subgroups of MS: MRI findings and correlation with histopathology. *Journal of the Neurological Sciences*, **2003**, 206, 173-4	3.2	12
558	Value of fluid-attenuated inversion recovery sequences in early MRI of the brain in neonates with a perinatal hypoxic-ischemic encephalopathy. *European Radiology*, **2000**, 10, 1594-601	8	12
557	Choosing drug therapy for multiple sclerosis. An update. *Drugs*, **1998**, 56, 555-69	12.1	12
556	Radiotherapy response of cerebral metastases quantified by serial MR imaging. *Journal of Neuro-Oncology*, **1994**, 21, 171-6	4.8	12
555	"Top of the basilar" syndrome: a comparison of clinical and MR findings. *Neuroradiology*, **1988**, 30, 293-8	3.2	12
554	MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). *Multiple Sclerosis Journal*, **1999**, 5, 283-286	5	12
553	Regional analysis of volumes and reproducibilities of automatic and manual hippocampal segmentations. *PLoS ONE*, **2017**, 12, e0166785	3.7	12
552	Comparison of two MR sequences for the detection of multiple sclerosis lesions in the spinal cord. *American Journal of Neuroradiology*, **1996**, 17, 1533-8	4.4	12
551	In vivo imaging of chronic active lesions in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 1352458520958589	5	12
550	Immune signatures of prodromal multiple sclerosis in monozygotic twins. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 21546-21556	11.5	12

549	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. *Brain*, **2021**, 144, 1296-1311	11.2	12
548	Subgenual Cingulate Cortex Functional Connectivity in Relation to Depressive Symptoms and Cognitive Functioning in Type 1 Diabetes Mellitus Patients. *Psychosomatic Medicine*, **2016**, 78, 740-9	3.7	12
547	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β. *Journal of Alzheimeris Disease*, **2017**, 55, 333-342	4.3	12
546	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. *Neurology*, **2021**, 97, e1898-e1905	6.5	12
545	Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 64 Suppl 1, S77-9	5.5	12
544	Automated fiber tract reconstruction for surgery planning: Extensive validation in language-related white matter tracts. *NeuroImage: Clinical*, **2019**, 23, 101883	5.3	11
543	Automatically computed rating scales from MRI for patients with cognitive disorders. *European Radiology*, **2019**, 29, 4937-4947	8	11
542	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. *Neurology*, **2020**, 95, e1027-e1040	6.5	11
541	Brain reward responses to food stimuli among female monozygotic twins discordant for BMI. *Brain Imaging and Behavior*, **2018**, 12, 718-727	4.1	11
540	Whole brain functional connectivity in clinically isolated syndrome without conventional brain MRI lesions. *European Radiology*, **2016**, 26, 2982-91	8	11
539	Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects. *NeuroImage: Clinical*, **2019**, 24, 101962	5.3	11
538	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. *Alzheimeris and Dementia*, **2019**, 15, 1458-1467	1.2	11
537	Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics. *Multiple Sclerosis Journal*, **2006**, 12, 565-72	5	11
536	MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a preliminary note). *American Journal of Neuroradiology*, **1998**, 19, 1857-62	4.4	11
535	Relationships between white matter hyperintensities, cerebral amyloid angiopathy and dementia in a population-based sample of the oldest old. *Current Alzheimer Research*, **2013**, 10, 1090-7	3	11
534	Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review. *Multiple Sclerosis Journal*, **2021**, 27, 1643-1656	5	11
533	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. *JAMA Neurology*, **2021**, 78, 351-364	17.2	11
532	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. *Multiple Sclerosis Journal*, **2019**, 25, 352-360	5	11

531	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. *Alzheimeris and Dementia*, **2020**, 16, 750-758	1.2	11
530	Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions **2018**, 59, 5025-5031		11
529	Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease. *Human Brain Mapping*, **2019**, 40, 3900-3909	3.9	10
528	Language comprehension in nonspeaking children with severe cerebral palsy: Neuroanatomical substrate?. *European Journal of Paediatric Neurology*, **2015**, 19, 510-20	3.8	10
527	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. *Journal of Alzheimeris Disease*, **2020**, 74, 213-225	4.3	10
526	Multimodal characterization of gray matter alterations in neuromyelitis optica. *Multiple Sclerosis Journal*, **2018**, 24, 1308-1316	5	10
525	Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. *European Radiology*, **2007**, 17, 67-71	8	10
524	How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis. *Annals of Neurology*, **2005**, 57, 606-7	9.4	10
523	Improved interobserver agreement for visual detection of active T2 lesions on serial MR scans in multiple sclerosis using image registration. *Journal of Neurology*, **2001**, 248, 789-94	5.5	10
522	Assessment of spinal cord damage in MS using MRI. *Journal of the Neurological Sciences*, **2000**, 172 Suppl 1, S36-9	3.2	10
521	Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. *Journal of Neurology*, **1999**, 246, 920-5	5.5	10
520	Disappearance of multiple sclerosis lesions with severely prolonged T1 on images obtained by a FLAIR pulse sequence. *Magnetic Resonance Imaging*, **1996**, 14, 209-13	3.3	10
519	Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial. *PLoS ONE*, **2014**, 9, e94483	3.7	10
518	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. *Alzheimeris Research and Therapy*, **2021**, 13, 169	9	10
517	Generalised boundary shift integral for longitudinal assessment of spinal cord atrophy. *NeuroImage* , **2020**, 209, 116489	7.9	10
516	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. *Translational Psychiatry*, **2020**, 10, 403	8.6	10
515	Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease-specific regions. *Neurobiology of Aging*, **2019**, 75, 109-116	5.6	10
514	Preoperative Resectability Estimates of Nonenhancing Glioma by Neurosurgeons and a Resection Probability Map. *Neurosurgery*, **2019**, 85, E304-E313	3.2	10

513	Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 481-490	5	10
512	Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab. *Multiple Sclerosis and Related Disorders*, **2019**, 33, 82-87	4	9
511	Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls. *NeuroImage: Clinical*, **2019**, 22, 101698	5.3	9
510	Accurate MR Image Registration to Anatomical Reference Space for Diffuse Glioma. *Frontiers in Neuroscience*, **2020**, 14, 585	5.1	9
509	White matter hyperintensities and vascular risk factors in monozygotic twins. *Neurobiology of Aging* , **2018**, 66, 40-48	5.6	9
508	Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders. *Journal of Magnetic Resonance Imaging*, **2018**, 47, 1601-1609	5.6	9
507	Cortical phase changes measured using 7-T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. *NMR in Biomedicine*, **2016**, 29, 1289-94	4.4	9
506	Functional brain network centrality is related to APOE genotype in cognitively normal elderly. *Brain and Behavior*, **2018**, 8, e01080	3.4	9
505	Contribution of white matter hyperintensities, medial temporal lobe atrophy and cortical atrophy on outcome, seven to twelve years after ECT in severely depressed geriatric patients. *Journal of Affective Disorders*, **2015**, 185, 144-8	6.6	9
504	Performance of the Swanton multiple sclerosis criteria for dissemination in space. *Multiple Sclerosis Journal*, **2010**, 16, 985-7	5	9
503	Motor testing at 1 year improves the prediction of motor and mental outcome at 2 years after perinatal hypoxic-ischaemic encephalopathy. *Developmental Medicine and Child Neurology*, **2010**, 52, 54-9	3.3	9
502	Magnetization transfer contrast (MTC) and long repetition time spin-echo MR imaging in multiple sclerosis. *Magnetic Resonance Imaging*, **1998**, 16, 351-8	3.3	9
501	Association between vitamin B6 and white matter hyperintensities in patients with Alzheimer's disease not mediated by homocysteine metabolism. *Journal of the American Geriatrics Society*, **2007** , 55, 956-8	5.6	9
500	Thallium-201 SPECT: the optimal prediction of response in glioma therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 222-7	8.8	9
499	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, **2007**, 68, 1163; author reply 1163-4	6.5	9
498	White-matter changes on MRI as surrogate marker. *International Psychogeriatrics*, **2003**, 15 Suppl 1, 261-5	3.4	9
497	Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels. *Journal of Neuroimmunology*, **2004**, 148, 172-7	3.5	9
496	Magnetic resonance image registration in multiple sclerosis: comparison with repositioning error and observer-based variability. *Journal of Magnetic Resonance Imaging*, **2002**, 15, 505-10	5.6	9

495	Comparison of film-screen combination and digital fluorography in gastrointestinal barium examinations in a clinical setting. *European Journal of Radiology*, **1996**, 22, 232-5	4.7	9
494	Gender-Related Association Between the TGFB1+869 Polymorphism and Multiple Sclerosis. *Journal of Interferon and Cytokine Research*, **2004**, 24, 536-542	3.5	9
493	Accelerated brain ageing and disability in multiple sclerosis		9
492	Hippocampal profiling: Localized magnetic resonance imaging volumetry and T2 relaxometry for hippocampal sclerosis. *Epilepsia*, **2020**, 61, 297-309	6.4	9
491	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. *Neurology*, **2020**, 95, e1672-e1685	6.5	9
490	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. *Alzheimeris and Dementia*, **2021**, 17, 1189-1204	1.2	9
489	Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. *Multiple Sclerosis Journal*, **2020**, 26, 1381-1391	5	9
488	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	9
487	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways **2000**, 10, 398		9
486	Interaction of Vascular Damage and Alzheimer Dementia: Focal Damage and Disconnection. *Radiology*, **2017**, 282, 311-313	20.5	8
485	High-dimensional detection of imaging response to treatment in multiple sclerosis. *Npj Digital Medicine*, **2019**, 2, 49	15.7	8
484	Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 1421-1431	5	8
483	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. *Journal of Neurology*, **2020**, 267, 3541-3554	5.5	8
482	Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 388-391	5.5	8
481	Quantitative MRI in hypomyelinating disorders: Correlation with motor handicap. *Neurology*, **2016**, 87, 752-8	6.5	8
480	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. *Dementia and Geriatric Cognitive Disorders*, **2016**, 41, 16-26	2.6	8
479	Medial temporal lobe atrophy and posterior atrophy scales normative values. *NeuroImage: Clinical*, **2019**, 24, 101936	5.3	8
478	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. *Multiple Sclerosis Journal*, **2011**, 17, 319-26	5	8

477	Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study. *American Journal of Neuroradiology*, **2011**, 32, 695-703	4.4	8
476	A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. *Neurology*, **2012**, 78, 841	6.5	8
475	Novel infantile-onset leukoencephalopathy with high lactate level and slow improvement. *Archives of Neurology*, **2012**, 69, 718-22		8
474	CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 246-8	5.5	8
473	Nonlinear changes in brain activity during continuous word repetition: an event-related multiparametric functional MR imaging study. *American Journal of Neuroradiology*, **2007**, 28, 1715-21	4.4	8
472	Differences in topological progression profile among neurodegenerative diseases from imaging data. *ELife*, **2019**, 8,	8.9	8
471	Molecular Imaging Approaches in Dementia. *Radiology*, **2021**, 298, 517-530	20.5	8
470	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. *Journal of Alzheimeris Disease*, **2019**, 68, 311-322	4.3	8
469	Can MRI be used as a proxy for ? A case study. *Brain Communications*, **2019**, 1, fcz030	4.5	8
468	A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 774-785	5	8
467	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 28-38	5	8
466	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. *European Radiology*, **2021**, 31, 5312-5323	8	8
465	Computer-assisted prediction of clinical progression in the earliest stages of AD. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 726-736	5.2	8
464	Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a systematic review. *Neuroradiology*, **2021**, 63, 1773-1789	3.2	8
463	Brain miliary enhancement. *Neuroradiology*, **2020**, 62, 283-300	3.2	7
462	White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. *American Journal of Neuroradiology*, **2016**, 37, 1030-7	4.4	7
461	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 1190-8	8.8	7
460	Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials. *Journal of Neurology*, **2004**, 251 Suppl 4, IV6-12	5.5	7

459	Gut Microbiota Composition Is Related to AD Pathology.. *Frontiers in Immunology*, **2021**, 12, 794519	8.4	7
458	Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. *Multiple Sclerosis Journal*, **2000**, 6, 280-285	5	7
457	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study. *Journal of Psychiatry and Neuroscience*, **2019**, 44, E1-E10	4.5	7
456	Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. *American Journal of Neuroradiology*, **1992**, 13, 1257-9	4.4	7
455	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2020**, 94, 71-80	5.6	7
454	CSF cutoffs for MCI due to AD depend on APOE ε4 carrier status. *Neurobiology of Aging*, **2020**, 89, 55-62	5.6	7
453	Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis. *Brain*, **2020**, 143, 2988-2997	11.2	7
452	Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event. *Brain*, **2021**, 144, 1409-1421	11.2	7
451	Quantifying eloquent locations for glioblastoma surgery using resection probability maps. *Journal of Neurosurgery*, **2020**, 134, 1091-1101	3.2	7
450	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis. *Neurology*, **2021**, 97, 474-488	6.5	7
449	Causes, effects and connectivity changes in MS-related cognitive decline. *Dementia E Neuropsychologia*, **2016**, 10, 2-11	2.1	7
448	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. *Magnetic Resonance Imaging*, **2021**, 76, 108-115	3.3	7
447	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. *Alzheimeris Research and Therapy*, **2021**, 13, 53	9	7
446	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.. *journal of prevention of Alzheimeris disease, The*, **2022**, 9, 197-210	3.8	7
445	Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities. *Journal of Neuroimaging*, **2017**, 27, 318-325	2.8	6
444	Impact of Gradient Number and Voxel Size on Diffusion Tensor Imaging Tractography for Resective Brain Surgery. *World Neurosurgery*, **2017**, 105, 923-934.e2	2.1	6
443	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 69-73	5.2	6
442	Accelerated executive functions decline and gray matter structural changes in middle-aged type 1 diabetes mellitus patients with proliferative retinopathy. *Journal of Diabetes*, **2018**, 10, 835-846	3.8	6

441	The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study. *European Radiology*, **2018**, 28, 1215-1226	8	6
440	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. *Journal of Neurology*, **2019**, 266, 2535-2545	5.5	6
439	Imaging phenotypes in multiple sclerosis. *Neuroimaging Clinics of North America*, **2015**, 25, 83-96	3	6
438	Quantitative MR Imaging and Spectroscopy in CongenitalCytomegalovirusInfection and Periventricular Leukomalacia Suggests a Comparable Neuropathological Substrate of the Cerebral White Matter Lesions. *Neuropediatrics*, **2009**, 40, 173-173	1.6	6
437	Magnetic resonance (MR) imaging as a marker for multiple sclerosis. *Biomedicine and Pharmacotherapy*, **1999**, 53, 351-7	7.5	6
436	Magnetic Resonance Imaging Hyperintensities in Alzheimer's Disease-Reply. *Archives of Neurology*, **1991**, 48, 469-470		6
435	Modelling new enhancing MRI lesion counts in multiple sclerosis. *Multiple Sclerosis Journal*, **2001**, 7, 298-304	3	6
434	Meningeal Gd-DTPA enhancement in multiple sclerosis. *American Journal of Neuroradiology*, **1992**, 13, 397-400	4.4	6
433	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. *Efficacy and Mechanism Evaluation*, **2020**, 7, 1-72	1.7	6
432	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services-part 1 of 6. *Alzheimeris Research and Therapy*, **2021**, 13, 168	9	6
431	Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. *Alzheimeris Research and Therapy*, **2020**, 12, 10	9	6
430	Spinal cord atrophy in a primary progressive multiple sclerosis trial: Improved sample size using GBSI. *NeuroImage: Clinical*, **2020**, 28, 102418	5.3	6
429	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. *Alzheimeris Research and Therapy*, **2020**, 12, 148	9	6
428	Cortical involvement determines impairment 30 years after a clinically isolated syndrome. *Brain*, **2021**, 144, 1384-1395	11.2	6
427	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. *NeuroImage: Clinical*, **2021**, 29, 102549	5.3	6
426	Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. *Multiple Sclerosis Journal*, **1996**, 1, 213-7	5	6
425	The presence of cerebral white matter lesions and lower skin microvascular perfusion predicts lower cognitive performance in type 1 diabetes patients with retinopathy but not in healthy controls-A longitudinal study. *Microcirculation*, **2019**, 26, e12530	2.9	5
424	Non-linear registration improves statistical power to detect hippocampal atrophy in aging and dementia. *NeuroImage: Clinical*, **2019**, 23, 101902	5.3	5

423	Minimal supportive treatment in natalizumab-related PML in a MS patient. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 354-5	5.5	5
422	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. *NeuroImage: Clinical*, **2020**, 28, 102504	5.3	5
421	Microbleeds are associated with depressive symptoms in Alzheimer's disease. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 112-120	5.2	5
420	Evaluation of prospective motion correction of high-resolution 3D-T2-FLAIR acquisitions in epilepsy patients. *Journal of Neuroradiology*, **2018**, 45, 368-373	3.1	5
419	A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2017**, 174, 220-226	3.5	5
418	Spinal cord MRI should always be performed in clinically isolated syndrome patients: Yes. *Multiple Sclerosis Journal*, **2014**, 20, 1688-9	5	5
417	Language comprehension in young people with severe cerebral palsy in relation to language tracts: a diffusion tensor imaging study. *Neuropediatrics*, **2013**, 44, 286-90	1.6	5
416	Normal Ageing **2011**, 43-57		5
415	A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. *European Radiology*, **2009**, 19, 2244-8	8	5
414	Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. *Multiple Sclerosis Journal*, **2007**, 13, 717-21	5	5
413	Guidelines for brain imaging in vascular dementia clinical trials. *International Psychogeriatrics*, **2003**, 15 Suppl 1, 273-6	3.4	5
412	Database for serial magnetic resonance imaging in multiple sclerosis. *Neuroradiology*, **1993**, 35, 362-6	3.2	5
411	Fingolimod Treatment Increases the Proportion of Patients Who Are Free from Disease Activity in Multiple Sclerosis Compared to IFN-b1a: Results from a Phase 3, Active-Controlled Study (TRANSFORMS) (PD5.006). *Neurology*, **2012**, 78, PD5.006-PD5.006	6.5	5
410	An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis: Advocacy, Dissemination, and Implementation Strategies. *International Journal of MS Care*, **2020**, 22, 226-232	2.3	5
409	Demyelinating Diseases of the CNS (Brain and Spine). *IDKD Springer Series*, **2020**, 165-176	1.1	5
408	Why Is Amyloid-PET Requested After Performing CSF Biomarkers?. *Journal of Alzheimeris Disease*, **2020**, 73, 559-569	4.3	5
407	Robust Deep Learning-based Segmentation of Glioblastoma on Routine Clinical MRI Scans Using Sparsified Training. *Radiology: Artificial Intelligence*, **2020**, 2, e190103	8.7	5
406	Brain structural and functional alterations in MOG antibody disease. *Multiple Sclerosis Journal*, **2021**, 27, 1350-1363	5	5

405	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. *American Journal of Neuroradiology*, **2020**, 41, 2209-2218	4.4	5
404	Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis: Cerebral blood flow and the heart-brain axis. *Alzheimeris and Dementia: Translational Research and Clinical Interventions*, **2020**, 6, e12034	6	5
403	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12063	5.2	5
402	Spatial concordance of DNA methylation classification in diffuse glioma. *Neuro-Oncology*, **2021**, 23, 2054-2065	11	5
401	Exploring resting state connectivity in patients with psychotic depression. *PLoS ONE*, **2019**, 14, e0209908	3.7	5
400	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2020**, 75, 1609-1617	6.4	5
399	Are Apathy and Depressive Symptoms Related to Vascular White Matter Hyperintensities in Severe Late Life Depression?. *Journal of Geriatric Psychiatry and Neurology*, **2021**, 34, 21-28	3.8	5
398	Clinical evaluation of automated quantitative MRI reports for assessment of hippocampal sclerosis. *European Radiology*, **2021**, 31, 34-44	8	5
397	Visual assessment of [F]flutemetamol PET images can detect early amyloid pathology and grade its extent. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2169-2182	8.8	5
396	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. *Journal of Alzheimeris Disease*, **2021**, 79, 1195-1201	4.3	5
395	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2157-2168	8.8	5
394	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. *Neurology*, **2021**, 96, e1561-e1573	6.5	5
393	Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. *Journal of Nutrition, Health and Aging*, **2006**, 10, 123-8; discussion 129-30	5.2	5
392	Voxelwise statistical methods to localize practice variation in brain tumor surgery. *PLoS ONE*, **2019**, 14, e0222939	3.7	4
391	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. *Journal of Alzheimeris Disease*, **2019**, 68, 1273-1286	4.3	4
390	Laminar cortical damage in multiple sclerosis. *Brain*, **2015**, 138, 828-9	11.2	4
389	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. *Neurobiology of Aging*, **2020**, 95, 104-114	5.6	4
388	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. *PLoS ONE*, **2020**, 15, e0226784	3.7	4

387	Direct comparison of [C] choline and [F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. *EJNMMI Research*, **2019**, 9, 57	3.6	4
386	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. *Alzheimeris and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 492-500	6	4
385	Multiple sclerosis: CCSVI deconstructed and discarded. *Nature Reviews Neurology*, **2013**, 9, 661-2	15	4
384	Diagnostic relevance of high field MRI in clinical neuroradiology: the advantages and challenges of driving a sports car. *European Radiology*, **2012**, 22, 2304-6	8	4
383	Severe irreversible optic neuritis following Mantoux tuberculin skin test in a child with multiple sclerosis--a case report. *Neuropediatrics*, **1997**, 28, 338-40	1.6	4
382	Quantitative computer-assisted analysis vs. visual estimation of MR imaging response of brain metastases to radiotherapy. *Magnetic Resonance Imaging*, **1997**, 15, 99-106	3.3	4
381	At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only. *Multiple Sclerosis Journal*, **2008**, 14, 428-30	5	4
380	Whole-brain T1-relaxation time measurements in multiple sclerosis. *Journal of Neurology*, **2002**, 249, 1451-2	5.5	4
379	SPECT, CT and MRI in a Turkish family with Huntington's disease. *Neuroradiology*, **1993**, 35, 525-8	3.2	4
378	Using Unsupervised Learning to Identify Clinical Subtypes of Alzheimer's Disease in Electronic Health Records. *Studies in Health Technology and Informatics*, **2020**, 270, 499-503	0.5	4
377	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. *Neurology*, **2021**,	6.5	4
376	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. *Journal of Alzheimeris Disease*, **2020**, 77, 1353-1368	4.3	4
375	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. *Journals of Gerontology - Series B Psychological Sciences and Social Sciences*, **2021**, 76, 1499-1511	4.6	4
374	Replication study of plasma proteins relating to Alzheimer's pathology. *Alzheimeris and Dementia*, **2021**, 17, 1452-1464	1.2	4
373	Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 13524585211010097	5	4
372	Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy. *Multiple Sclerosis Journal*, **2021**, 13524585211008743	5	4
371	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. *Alzheimeris and Dementia*, **2021**, 17, 1628-1640	1.2	4
370	Neuroimaging in Dementia **2016**, 79-85		4

369	Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. *Alzheimeris and Dementia: Translational Research and Clinical Interventions*, **2016**, 2, 233-240	6	4
368	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. *Multiple Sclerosis Journal*, **2019**, 25, 565-573	5	4
367	Cerebral effects of glucagon-like peptide-1 receptor blockade before and after Roux-en-Y gastric bypass surgery in obese women: A proof-of-concept resting-state functional MRI study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 415-424	6.7	4
366	The sequence of structural, functional and cognitive changes in multiple sclerosis. *NeuroImage: Clinical*, **2021**, 29, 102550	5.3	4
365	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. *Alzheimeris Research and Therapy*, **2021**, 13, 138	9	4
364	Subtyping relapsing-remitting multiple sclerosis using structural MRI. *Journal of Neurology*, **2021**, 268, 1808-1817	5.5	4
363	The protective gene dose effect of the APOE 2 allele on gray matter volume in cognitively unimpaired individuals. *Alzheimeris and Dementia*, **2021**,	1.2	4
362	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2017**, 50, 77-86	5.6	3
361	Differential impact of subclinical carotid artery disease on cerebral structure and functioning in type 1 diabetes patients with versus those without proliferative retinopathy. *Cardiovascular Diabetology*, **2014**, 13, 58	8.7	3
360	Making better use of our brain MRI research data. *European Radiology*, **2012**, 22, 1395-6	8	3
359	Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients. *Dementia and Geriatric Cognitive Disorders*, **2010**, 29, 301-8	2.6	3
358	Localisation of the central sulcus region in glioma patients with three-dimensional fluid-attenuated inversion recovery and volume rendering: comparison with functional and conventional magnetic resonance. *British Journal of Neurosurgery*, **2011**, 25, 210-7	1	3
357	Modeling MR imaging enhancing-lesion volumes in multiple sclerosis: application in clinical trials. *American Journal of Neuroradiology*, **2011**, 32, 2093-7	4.4	3
356	Methylprednisolone treatment in multiple sclerosis: effect of treatment, pharmacokinetics, future. *Multiple Sclerosis Journal*, **1996**, 1, 327-8	5	3
355	Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. *Multiple Sclerosis Journal*, **2000**, 6, 99-104	5	3
354	The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee. *Neurology*, **2004**, 63, 1140; author reply 1140	6.5	3
353	Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. *Annals of Clinical and Translational Neurology*, **2021**, 8, 2235	5.3	3
352	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. *JMIR Research Protocols*, **2018**, 7, e80	2	3

351	Learning to Segment When Experts Disagree. *Lecture Notes in Computer Science*, **2020**, 179-190	0.9	3
350	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. *Brain Communications*, **2020**, 2, fcaa177	4.5	3
349	Comorbid amyloid-β pathology affects clinical and imaging features in VCD. *Alzheimeris and Dementia*, **2020**, 16, 354-364	1.2	3
348	Relationship between β amyloid and structural network topology in decedents without dementia. *Neurology*, **2020**, 95, e532-e544	6.5	3
347	DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease. *American Journal of Clinical Nutrition*, **2021**, 113, 1627-1635	7	3
346	Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 709-716	5.5	3
345	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. *Alzheimeris Research and Therapy*, **2021**, 13, 82	9	3
344	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. *Frontiers in Aging Neuroscience*, **2021**, 13, 712545	5.3	3
343	[F]Flortaucipir PET Across Various Mutations in Presymptomatic and Symptomatic Carriers. *Neurology*, **2021**, 97, e1017-e1030	6.5	3
342	Single-subject structural cortical networks in clinically isolated syndrome. *Multiple Sclerosis Journal*, **2020**, 26, 1392-1401	5	3
341	Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 177-188	5.5	3
340	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. *Alzheimeris and Dementia*, **2021**, 17, 205-214	1.2	3
339	Grey zone amyloid burden affects memory function: the SCIENCe project. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 747-756	8.8	3
338	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. *NeuroImage: Clinical*, **2021**, 30, 102660	5.3	3
337	Amyloid-β cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. *Annals of Clinical and Translational Neurology*, **2021**, 8, 348-358	5.3	3
336	P1-401: INVESTIGATING ARTERIAL SPIN LABELING AS A LARGE VESSEL CORRELATE OF SVD, AD, AND PD **2018**, 14, P456-P456		3
335	Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder. *Multiple Sclerosis Journal*, **2021**, 13524585211032800	5	3
334	MRI Natural History of the Leukodystrophy Vanishing White Matter. *Radiology*, **2021**, 300, 671-680	20.5	3

333	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.. *Neurology*, **2022**,	6.5	3
332	Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. *NeuroImage: Clinical*, **2022**, 35, 103048	5.3	3
331	Diagnostic algorithm for relapsing demyelinating syndromes of the CNS in children. *Lancet, The*, **2017**, 389, S41	40	2
330	Novel imaging phantom for accurate and robust measurement of brain atrophy rates using clinical MRI. *NeuroImage: Clinical*, **2019**, 21, 101667	5.3	2
329	Highly accurate volumetry of the spinal cord **2015**,		2
328	Converging evidence for a gray-zone of amyloid burden and its relevance. *Alzheimeris and Dementia*, **2020**, 16, e044786	1.2	2
327	The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary. *Multiple Sclerosis Journal*, **2018**, 24, 125-126	5	2
326	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. *Journal of Alzheimeris Disease*, **2018**, 65, 71-77	4.3	2
325	Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process. *NeuroImage: Clinical*, **2019**, 24, 102051	5.3	2
324	No influence of KIF1B on neurodegenerative markers in multiple sclerosis. *Neurology*, **2011**, 76, 1843-5	6.5	2
323	Fetal Origin of Brain Damage in 2 Infants with aCOL4A1Mutation: Fetal and Neonatal MRI. *Neuropediatrics*, **2011**, 42, e1-e1	1.6	2
322	Suspected early dementia. *BMJ, The*, **2011**, 343, d5568	5.9	2
321	Multi-Contrast, Isotropic, Single-Slab 3D MR Imaging in Multiple Sclerosis. *Neuroradiology Journal*, **2009**, 22, 33-42	2	2
320	Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images. *Annals of Neurology*, **1997**, 42, 982	9.4	2
319	The role of spinal cord imaging in the diagnosis of multiple sclerosis. *Nature Clinical Practice Neurology*, **2006**, 2, 283-6; quiz 287		2
318	Association of APOE polymorphisms with disease severity in MS is limited to women. *Neurology*, **2004**, 63, 1139; author reply 1139	6.5	2
317	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease		2
316	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12060	5.2	2

315	Sex differences in memory clinic patients with possible vascular cognitive impairment. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12090	5.2	2
314	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [F]FDG-PET and pathological assessment. *Neurocase*, **2021**, 27, 181-189	0.8	2
313	Glioblastoma Surgery Imaging-Reporting and Data System: Standardized Reporting of Tumor Volume, Location, and Resectability Based on Automated Segmentations. *Cancers*, **2021**, 13,	6.6	2
312	Parametric imaging of dual-time window [F]flutemetamol and [F]florbetaben studies. *NeuroImage*, **2021**, 234, 117953	7.9	2
311	Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. *Neuroradiology*, **2020**, 62, 1257-1263	3.2	2
310	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. *Multiple Sclerosis Journal*, **2021**, 27, 968-972	5	2
309	Risk of dementia in 4 carriers is mitigated by a polygenic risk score. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12229	5.2	2
308	FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis. *NeuroImage: Clinical*, **2021**, 29, 102542	5.3	2
307	White matter microstructure disruption in early stage amyloid pathology. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12124	5.2	2
306	Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	2
305	IC-P-192: DISEASE-STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P158-P160		2
304	Earliest radiological progression in glioblastoma by multidisciplinary consensus review. *Journal of Neuro-Oncology*, **2018**, 139, 591-598	4.8	2
303	Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. *Acta Neuropathologica Communications*, **2021**, 9, 131	7.3	2
302	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. *Brain Communications*, **2021**, 3, fcab201	4.5	2
301	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. *Neurobiology of Aging*, **2021**, 105, 252-261	5.6	2
300	Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study **1997**, 7, 594		2
299	Mild cognitive impairment with Lewy bodies: Clinical characteristics and risk factors for progression. *Alzheimeris and Dementia*, **2020**, 16, e039094	1.2	1
298	Dynamic PET imaging reduces sample sizes to detect longitudinal amyloid accumulation. *Alzheimeris and Dementia*, **2020**, 16, e042623	1.2	1

297	Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance. *Journal of Neurology*, **2020**, 267, 3287-3291	5.5	1
296	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic **2016**, 12, P393-P393		1
295	Daclizumab in multiple sclerosis: a high-yield extension study. *Lancet Neurology, The*, **2014**, 13, 443-4	24.1	1
294	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION **2014**, 10, P402-P402		1
293	P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA **2014**, 10, P541-P542		1
292	O4-07-05: ADDED VALUE OF MRI BIOMARKERS TO NEUROPSYCHOLOGICAL TEST PERFORMANCE FOR PREDICTION OF AD IN SUBJECTS WITH MCI **2014**, 10, P265-P265		1
291	P1-255: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSD STUDY **2014**, 10, P400-P401		1
290	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE **2014**, 10, P61-P61		1
289	P2-196: RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA□TWO SIDES OF THE SAME COIN? **2014**, 10, P543-P543		1
288	[P3□86]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI **2017**, 13, P1108-P1108		1
287	[P1□95]: AMYPAD: A EUROPEAN PUBLIC-PRIVATE PARTNERSHIP TO INVESTIGATE THE VALUE OF □AMYLOID BRAIN SCANS AS A DIAGNOSTIC AND THERAPEUTIC MARKER FOR ALZHEIMER's DISEASE **2017**, 13, P420-P420		1
286	[P2□12]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY **2017**, 13, P691-P692		1
285	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease **2015**, 11, P806-P807		1
284	IC-P-072: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSD STUDY **2014**, 10, P40-P40		1
283	Imaging Alzheimer in 2011. *Neuroradiology*, **2011**, 53 Suppl 1, S145-7	3.2	1
282	Segmental muscular atrophy of the distal upper extremity (Hirayama disease): An atypical case with anterior dural detachment. *European Journal of Radiology Extra*, **2009**, 72, e53-e55		1
281	Methylprednisolone for Acute Relapses of Multiple Sclerosis. *CNS Drugs*, **1998**, 10, 233-238	6.7	1
280	Feature extraction and strategy of analyzing structural neuroimaging in dementia. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2008**, 89, 75-86	3	1

279	Microvasculaire schade en cognitieve achteruitgang bij type-1-diabetes. *Neuropraxis*, **2007**, 11, 32-37	0	1
278	DNA methylation classification in diffuse glioma shows little spatial heterogeneity after adjusting for tumor purity		1
277	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. *Multiple Sclerosis Journal*, **2022**, 13524585211061861	5	1
276	Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence. *Neurology*, **2021**, 97, 989-999	6.5	1
275	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. *Multiple Sclerosis Journal*, **2021**, 13524585211045545	5	1
274	A deep learning algorithm for white matter hyperintensity lesion detection and segmentation. *Neuroradiology*, **2021**, 1	3.2	1
273	Genome-wide association study of Alzheimer disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset		1
272	ExploreASL: an image processing pipeline for multi-center ASL perfusion MRI studies		1
271	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.. *Multiple Sclerosis and Related Disorders*, **2022**, 57, 103364	4	1
270	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. *Lecture Notes in Computer Science*, **2016**, 104-112	0.9	1
269	Disorders Mainly Affecting White Matter **2011**, 177-242		1
268	Magnetic Resonance and Dementia **2002**, 1-4		1
267	Application of mechanistic methods to clinical trials in multiple sclerosis: the simvastatin case		1
266	Data-driven detection of latent atrophy factors related to phenotypical variants of posterior cortical atrophy		1
265	Differential Dementia Diagnosis on Incomplete Data with Latent Trees. *Lecture Notes in Computer Science*, **2016**, 44-52	0.9	1
264	Progression of regional grey matter atrophy in multiple sclerosis		1
263	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12077	5.2	1
262	Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 20552173211013831	2	1

261	Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 995-1006	5.5	1
260	Uncertainty analysis of MR-PET image registration for precision neuro-PET imaging. *NeuroImage*, **2021**, 232, 117821	7.9	1
259	Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis. *Neurology*, **2021**, 97, e794-e802	6.5	1
258	The natural history of primary progressive aphasia: beyond aphasia. *Journal of Neurology*, **2021**, 1	5.5	1
257	Transient Cognitive Impairment and White Matter Hyperintensities in Severely Depressed Older Patients Treated With Electroconvulsive Therapy. *American Journal of Geriatric Psychiatry*, **2021**, 29, 1117-1128	6.5	1
256	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12216	5.2	1
255	IC-P-182: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL AMYLOID DEPOSITION IN THE BRAIN **2018**, 14, P152-P152		1
254	P2-505: REGIONAL DISTRIBUTION OF WHITE MATTER HYPERINTENSITY CORRELATES WITH COGNITION IN THE ALFA COHORT **2018**, 14, P925-P925		1
253	IC-P-092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY **2018**, 14, P76-P79		1
252	P4-106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD **2018**, 14, P1479-P1479		1
251	P2-445: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL AMYLOID DEPOSITION IN THE BRAIN **2018**, 14, P887-P888		1
250	Multiple Sclerosis and Variants **2018**, 1-41		1
249	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. *Frontiers in Neurology*, **2021**, 12, 693333	4.1	1
248	Non-invasively measured brain activity and radiological progression in diffuse glioma. *Scientific Reports*, **2021**, 11, 18990	4.9	1
247	Quantification of amyloid PET for future clinical use: a state-of-the-art review.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	1
246	Identifying and evaluating clinical subtypes of Alzheimer's disease in care electronic health records using unsupervised machine learning. *BMC Medical Informatics and Decision Making*, **2021**, 21, 343	3.6	1
245	Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. *Alzheimeris and Dementia*, **2021**, 17,	1.2	1
244	Damage in the Thalamocortical Tracts is Associated With Subsequent Thalamus Atrophy in Early Multiple Sclerosis. *Frontiers in Neurology*, **2020**, 11, 575611	4.1	0

243	Neuromyelitis Optica Spectrum Disorders (NMOSD) **2019**, 769-785		0
242	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS **2014**, 10, P42-P43		0
241	The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.. *European Radiology*, **2022**, 1	8	0
240	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.. *Brain Communications*, **2022**, 4, fcac026	4.5	0
239	Amyloid-β p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease.. *Brain Communications*, **2021**, 3, fcab281	4.5	0
238	Seeing more with less: virtual gadolinium-enhanced glioma imaging. *The Lancet Digital Health*, **2021**, 3, e754-e755	14.4	0
237	Degenerative adversarial neuroimage nets for brain scan simulations: Application in ageing and dementia. *Medical Image Analysis*, **2021**, 75, 102257	15.4	0
236	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function **2016**, 12, P113-P114		0
235	Biomarker testing in MCI patients-deciding who to test. *Alzheimeris Research and Therapy*, **2021**, 13, 14	9	0
234	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. *NeuroImage: Clinical*, **2021**, 30, 102659	5.3	0
233	On the cutting edge of glioblastoma surgery: where neurosurgeons agree and disagree on surgical decisions. *Journal of Neurosurgery*, **2021**, 1-11	3.2	0
232	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. *NeuroImage: Clinical*, **2021**, 31, 102725	5.3	0
231	MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies.. *NeuroImage: Clinical*, **2022**, 34, 102972	5.3	0
230	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. *Cerebral Circulation - Cognition and Behavior*, **2022**, 3, 100141	0	0
229	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. *Frontiers in Aging Neuroscience*, **2022**, 14, 840651	5.3	0
228	Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study.. *Multiple Sclerosis and Related Disorders*, **2022**, 60, 103713	4	0
227	A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue.. *Magnetic Resonance Materials in Physics, Biology, and Medicine*, **2021**, 35, 163	2.8	0
226	Impact of cerebral blood flow and amyloid load on SUVR bias.. *EJNMMI Research*, **2022**, 12, 29	3.6	0

225	Post-mortem correlates of Virchow-Robin spaces detected on MRI.. *Journal of Cerebral Blood Flow and Metabolism*, **2022**, 271678X211067455	7.3	0
224	[IC-P-130]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY **2017**, 13, P98-P99		
223	[P1□92]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA **2017**, 13, P417-P418		
222	Neuromyelitis Optica Spectrum Disorders (NMOSD) **2019**, 1-17		
221	IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease. *Lancet Neurology, The*, **2019**, 18, 519-520	24.1	
220	Leukodystrophies and Inherited Metabolic Conditions **2019**, 1-36		
219	Transient gadolinium leakage in natalizumab-treated multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 475-6	5.5	
218	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. *Alzheimeris and Dementia*, **2020**, 16, e037912	1.2	
217	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated segmentation in old and young healthy volunteers. *Alzheimeris and Dementia*, **2020**, 16, e040322	1.2	
216	Amyloid-□deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. *Alzheimeris and Dementia*, **2020**, 16, e040991	1.2	
215	ExploreQC: A toolbox for MRI quality control in the EPAD multicentre study. *Alzheimeris and Dementia*, **2020**, 16, e041952	1.2	
214	Polygenic risk score for Alzheimer□ disease is related to amyloid positivity in subjective cognitive decline: The SCIENCe project. *Alzheimeris and Dementia*, **2020**, 16, e042116	1.2	
213	Differential diagnosis of dementia combining web-based cognitive testing and MRI. *Alzheimeris and Dementia*, **2020**, 16, e042626	1.2	
212	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. *Alzheimeris and Dementia*, **2020**, 16, e042628	1.2	
211	Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. *Alzheimeris and Dementia*, **2020**, 16, e042653	1.2	
210	Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. *Alzheimeris and Dementia*, **2020**, 16, e042687	1.2	
209	Biomarker testing in MCI patients: Deciding who to tap. *Alzheimeris and Dementia*, **2020**, 16, e042735	1.2	
208	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. *Alzheimeris and Dementia*, **2020**, 16, e042739	1.2	

207	Amyloid-β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. *Alzheimeris and Dementia*, **2020**, 16, e042768	1.2
206	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. *Alzheimeris and Dementia*, **2020**, 16, e042892	1.2
205	A multi-study analysis of the spatial-temporal progression of amyloid deposition and its utility for longitudinal studies. *Alzheimeris and Dementia*, **2020**, 16, e044707	1.2
204	Current status and quantitative results of the AMYPAD prognostic and natural history study. *Alzheimeris and Dementia*, **2020**, 16, e044711	1.2
203	Amyloid-dependent association of grey matter network disruptions with phospho-tau in preclinical Alzheimer's disease. *Alzheimeris and Dementia*, **2020**, 16, e044739	1.2
202	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. *Alzheimeris and Dementia*, **2020**, 16, e045196	1.2
201	Grey zone amyloid burden heralds future memory decline: The SCIENCe Project. *Alzheimeris and Dementia*, **2020**, 16, e045210	1.2
200	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18F]flortaucipir, [11C]UCB-J and magnetoencephalography study. *Alzheimeris and Dementia*, **2020**, 16, e045806	1.2
199	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. *Alzheimeris and Dementia*, **2020**, 16, e045876	1.2
198	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomal-dominant Alzheimer disease depend on imaging modality. *Alzheimeris and Dementia*, **2020**, 16, e045942	1.2
197	Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET. *Alzheimeris and Dementia*, **2020**, 16, e045991	1.2
196	Response: Brain miliary enhancement. *Neuroradiology*, **2020**, 62, 547	3.2
195	Author response: Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. *Neurology*, **2020**, 94, 330	6.5
194	Peri-hippocampal developmental venous anomalies and memory loss: more than a normal variant?. *Neuroradiology*, **2018**, 60, 579-582	3.2
193	P2-250: Reduced White Matter Integrity of the Rostral Limbic System Pathways in Healthy Elderly APOE E4 Allele Carriers **2016**, 12, P721-P721	
192	P2-342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function **2016**, 12, P774-P774	
191	ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, e1.30-e1	5.5
190	Leukodystrophies and Inherited Metabolic Conditions **2019**, 1641-1675	

189 Multiple Sclerosis and Variants **2019**, 727-767

188 Neuroimaging in Normal Brain Aging **2019**, 1277-1293

187 Neuroimaging in Dementia **2019**, 1295-1325

186 Neurodegenerative Disorders: Classification and Imaging Strategy **2019**, 1251-1275

185 Reproducing Fingerprints: A Step toward Clinical Adoption. *Radiology*, **2019**, 292, 438-439 20.5

184 O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY **2014**, 10, P291-P292

183 O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA **2014**, 10, P194-P195

182 P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE **2014**, 10, P385-P386

181 IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE **2014**, 10, P48-P49

180 IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA **2014**, 10, P37-P37

179 P1-235: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS **2014**, 10, P390-P391

178 P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE **2014**, 10, P455-P456

177 O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS **2014**, 10, P178-P179

176 O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA **2014**, 10, P300-P300

175 IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS **2014**, 10, P32-P33

174 IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY **2014**, 10, P43-P44

173 IC-P-224: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS **2014**, 10, P120-P121

172 IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE **2014**, 10, P31-P32

171 P1-233: MULTIMODAL BRAIN NETWORK ALTERATIONS IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT PATIENTS **2014**, 10, P389-P390

170 O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD **2014**, 10, P132-P133

169 IC-P-179: REDUCED CALLOSAL WHITE MATTER INTEGRITY SURPASSES CEREBROSPINAL FLUID AND ATROPHY MARKERS AS PREDICTOR OF DECLINE IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT: A COMBINED VOLUMETRY AND DTI STUDY **2014**, 10, P100-P100

168 P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME **2014**, 10, P363-P363

167 P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT **2014**, 10, P465-P466

166 P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS **2014**, 10, P540-P541

165 IC-P-106: Reproducibility of hippocampal atrophy rate at 1.5T and 3T for freesurfer and MAPS-HBSI using the ADNI1 data set **2015**, 11, P72-P73

164 P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly **2015**, 11, P689-P689

163 P3-146: Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: A multicenter DTI and volumetry study **2015**, 11, P682-P682

162 IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia **2015**, 11, P85-P85

161 P4-088: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease **2015**, 11, P806-P806

160 [P2□45]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER's DISEASE PATIENTS WITH CURCUMIN **2017**, 13, P705-P706

159 [P2□99]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P783-P783

158 [P2□18]: METHODOLOGICAL AND LOGISTIC STRATEGIES FOR A LARGE MULTI-CENTER □AMYLOID PET EUROPEAN PROJECT: AMYLOID IMAGING TO PREVENT ALZHEIMER's DISEASE (AMYPAD) **2017**, 13, P794-P794

157 [P3□62]: ACROSS-SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI-SITE 3T STUDY **2017**, 13, P954-P955

156 [P3□75]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT **2017**, 13, P1102-P1103

155 [P3□89]: WHEN MEASURING HIPPOCAMPAL ATROPHY, DO THE SEGMENTATION NOISE DISTRIBUTIONS OF METHODS, AS DETERMINED BY THE BACK-TO-BACK REPRODUCIBILITY, HAVE GAUSSIAN DISTRIBUTIONS? **2017**, 13, P1109-P1111

154 [P3□22]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA **2017**, 13, P1127-P1128

153 [P4□26]: BEST COMBINATORIAL LOW-COST MARKERS TO PREDICT MCI CONVERSION: AN EMIF-AD FEDERATION STUDY **2017**, 13, P1356-P1357

152 [IC-P-036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P32-P32

151 [IC-P-053]: EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS **2017**, 13, P43-P44

150 [IC-P-055]: EFFECT OF APOE-□ ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE **2017**, 13, P45-P46

149 [IC-P-065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P53-P54

148 [IC-P-085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT **2017**, 13, P69-P69

147 [IC-P-095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE **2017**, 13, P74-P75

146 [IC-P-106]: PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE **2017**, 13, P81-P82

145 [IC-P-110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P87-P87

144 [IC-P-132]: WHEN MEASURING HIPPOCAMPAL ATROPHY, DO THE SEGMENTATION NOISE DISTRIBUTIONS OF METHODS, AS DETERMINED BY THE BACK TO BACK REPRODUCIBILITY, HAVE GAUSSIAN DISTRIBUTIONS? **2017**, 13, P99-P101

143 [IC-P-167]: ACROSS-SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI-SITE 3T STUDY **2017**, 13, P126-P127

142 [P1□89]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A□ OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2017**, 13, P361-P362

141 [P1□00]: USING SUBTRACTION MRI TO IMPROVE THE DETECTION OF AMYLOID-RELATED IMAGING ABNORMALITIES WITH EDEMA OR EFFUSION (ARIA-E) IN PATIENTS AFFECTED BY ALZHEIMER's DISEASE RECEIVING IMMUNOTHERAPY: AN INTER-OBSERVER STUDY **2017**, 13, P425-P427

140 [P1□04]: EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS **2017**, 13, P429-P429

139 [P1□11]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P433-P434

138 [P1□40]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P451-P451

137 [P2□35]: EFFECT OF APOE □ ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE **2017**, 13, P748-P750

136 [F1□03□04]: BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P177

135 [O1□01□02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE **2017**, 13, P182

134 [O2□01□01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE) **2017**, 13, P547-P548

133 [O2□10□06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM **2017**, 13, P579

132 [O2□11□03]: PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE **2017**, 13, P581-P582

131 [P4□524]: WHITE MATTER HYPERINTENSITIES ARE ASSOCIATED WITH HIPPOCAMPAL ATROPHY RATES AFTER ADJUSTING FOR OTHER VASCULAR MARKERS IN PREDEMENTIA DISEASE STAGES **2017**, 13, P1547-P1548

130 [P4□526]: HARMONIZATION OF NEUROIMAGING BIORMARKERS FOR NEURODEGENERATIVE DISEASES: A SURVEY FOR BEST PRACTICE GUIDELINES **2017**, 13, P1549-P1550

129 [DT-01□02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT **2017**, 13, P1474-P1475

128 P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease **2015**, 11, P414-P414

127 SUSTAINED LOW RATE BRAIN VOLUME LOSS IN LONG TERM FINGOLIMOD TREATMENT. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, e4.19-e4 5.5

126 IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease **2015**, 11, P57-P57

125 IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly **2015**, 11, P11-P11

124 IC-P-092: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning **2015**, 11, P64-P64

123 IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease **2015**, 11, P46-P47

122 EFFECT OF FINGOLIMOD VS. IFN-BETA1A ON NO EVIDENCE OF DISEASE ACTIVITY. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, e4.18-e4 5.5

121 F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease **2015**, 11, P168-P168

120 IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent? **2015**, 11, P62-P62

119 IC-P-093: Distinct patterns of atrophy in postmortem confirmed dementias **2015**, 11, P64-P65

118 IC-P-105: Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: A□multicenter DTI and volumetry study **2015**, 11, P72-P72

117	IC-P-108: Impact of ApoE-ε4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults **2015**, 11, P73-P73	
116	P3-170: Reproducibility of hippocampal atrophy rate at 1.5T and 3T for freesurfer and MAPS-HBSI using the ADNI1 data set **2015**, 11, P694-P695	
115	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent? **2015**, 11, P814-P814	
114	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset **2015**, 11, P140-P142	
113	O2-09-01: Impact of ApoE-e4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults **2015**, 11, P194-P194	
112	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool **2015**, 11, P254-P255	
111	O4-08-05: Distinct patterns of atrophy in postmortem-confirmed dementias **2015**, 11, P288-P289	
110	O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning **2015**, 11, P289-P289	
109	O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression **2015**, 11, P317-P317	
108	O4-03-01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease **2012**, 8, P618-P618	
107	Demyelinating Diseases **2012**, 50-57	
106	Efficient use of MRI for dose finding in multiple sclerosis. *Lancet Neurology, The*, **2013**, 12, 730-1	24.1
105	PS12 - 6. Selective cognitive decline is related to focal brain volume loss in type 1 diabetes patients with microangiopathy: a 4 year follow-up. *Nederlands Tijdschrift Voor Diabetologie*, **2013**, 11, 179-180	0
104	Imaging of gray matter lesions in multiple sclerosis165-174	
103	Use of Imaging in Multiple Sclerosis **2010**, 35-51	
102	PS1 - 4. Widespread decreased white matter tract integrity in T1DM patients with microangiopathy and its relation to cognitive functions. *Nederlands Tijdschrift Voor Diabetologie*, **2011**, 9, 93-93	0
101	PS11 - 50. Depressive symptoms exacerbate the negative effects of type 1 diabetes and microangiopathy on brain functioning. *Nederlands Tijdschrift Voor Diabetologie*, **2012**, 10, 133-133	0
100	Use of Imaging in Multiple Sclerosis45-62	

99	Assessing Treatment Effects on Axonal Loss - Evidence from MRI Monitored Clinical Trials. *The Neuroradiology Journal*, **2005**, 18, 486-492	
98	NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. *Neurology*, **2005**, 65, 1341	6.5
97	MRI enhancing lesion frequency from patients with MS enrolled in the placebo arms of clinical trials or in natural history studies. *Magnetic Resonance Imaging*, **1999**, 17, 1236-7	3.3
96	Presumed small vessel disease, imaging and cognition markers in the Alzheimer's Disease Neuroimaging Initiative. *Brain Communications*, **2021**, 3, fcab226	4.5
95	Magnetic Resonance: Applications in Dementia **2002**, 5-25	
94	Neurodegenerative Disorders **2002**, 31-138	
93	Disorders Primarily Affecting White Matter **2002**, 139-230	
92	Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: a Phase I/II Study with Riluzole **2004**, 41-47	
91	5 Beeldvormend onderzoek **2009**, 43-51	
90	Dementia: Clinical Background **2011**, 5-11	
89	Primary Grey Matter Loss **2011**, 59-135	
88	Imaging Alzheimer in 2011 **2012**, 217-219	
87	MS-SMART study: systematic sampling bias concerns - Authors' reply. *Lancet Neurology, The*, **2020**, 19, 479-480	24.1
86	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients **2016**, 12, P9-P10	
85	P2-221: Cerebral Blood Flow Measured with Phase-Contrast MRI in AD, MCI and Controls **2016**, 12, P706-P706	
84	O3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status **2016**, 12, P303-P303	
83	P1-178: Impact of Co-Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders **2016**, 12, P472-P472	
82	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs **2016**, 12, P7-P8	

81 P1-284: Grey Matter Connectivity is Associated With Clinical Progression in Non-Demented, Amyloid Positive Patients **2016**, 12, P528-P529

80 P1-327: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease **2016**, 12, P552-P553

79 IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer Disease **2016**, 12, P78-P79

78 IC-P-106: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease **2016**, 12, P80-P81

77 IC-P-108: Cerebral Blood Flow Measured With Phase-Contrast MRI in AD, MCI and Controls **2016**, 12, P82-P82

76 IC-P-133: The Measurement of Hippocampal Atrophy Rates With MRI for A 3-Year Study Appears to be at Least 3 Times More Sensitive Than A 1-Year Study Based on Back-To-Back Reproducibility **2016**, 12, P99-P100

75 IC-P-147: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology **2016**, 12, P109-P110

74 P3-144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts **2016**, 12, P873-P874

73 P3-269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs **2016**, 12, P935-P936

72 P4-191: A Novel Neuroimaging Approach to Capture Cognitive Reserve **2016**, 12, P1095-P1096

71 P4-220: The Measurement of Hippocampal Atrophy Rates With MRI for A 3-Year Study Appears to Be at Least 3 Times More Sensitive Than A 1-Year Study Based on Back-To-Back Reproducibility **2016**, 12, P1112-P1113

70 O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer Disease **2016**, 12, P169-P170

69 O4-02-04: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology **2016**, 12, P335-P336

68 O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases **2016**, 12, P355-P355

67 P1-174: Cost-Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach **2016**, 12, P469-P470

66 IC-P-159: AMYLOID-BETA ACCUMULATION AFFECTS IN VIVO STAGING OF TAU DEPOSITION IN COGNITIVELY IMPAIRED INDIVIDUALS **2019**, 15, P127-P128

65 IC-P-025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE **2019**, 15, P32-P33

64 IC-02-01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE **2019**, 15, P1-P1

63 IC-P-076: FDG-PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY-DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE **2019**, 15, P68-P70

62 IC-P-015: VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM **2019**, 15, P24-P25

61 IC-P-097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING **2019**, 15, P84-P85

60 Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study. *Neuro-Oncology Advances*, **2021**, 3, vdab053 0.9

59 P3-403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE **2018**, 14, P1257-P1257

58 O3-13-01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE **2018**, 14, P1054-P1055

57 P1-476: CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS **2018**, 14, P506-P507

56 O1-14-04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION-SYMPTOM MAPPING STUDY **2018**, 14, P259-P259

55 P3-216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIF-AD 90+ STUDY **2018**, 14, P1153-P1153

54 IC-P-222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM **2018**, 14, P180-P181

53 IC-P-066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS **2018**, 14, P59-P60

52 P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2018**, 14, P1161-P1161

51 P1-016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAM-VCI STUDY **2018**, 14, P270-P271

50 IC-P-119: POSTERIOR ATROPHY SCALE: NORMATIVE VALUES FOR ITALIAN POPULATION **2018**, 14, P101-P102

49 IC-06-05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE **2018**, 14, P13-P13

48 P1-418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS **2018**, 14, P465-P465

47 P1-297: METABOLIC BLOOD-BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE **2018**, 14, P401-P403

46 P1-478: LOWER STRUCTURAL DEGREE AND HIGHER LOCAL EFFICIENCY RELATED TO DIFFUSE AMYLOID-BETA LOAD IN CORTEX OF NON-NEUROLOGICAL AGED DONORS **2018**, 14, P508-P508

45 P2-349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA **2018**, 14, P820-P821

44 P2-363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS **2018**, 14, P830-P831

43 F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P204-P204

42 P3-436: MECHANISTIC PROFILES OF NEURODEGENERATION: A STUDY IN ALZHEIMER'S DISEASE, HEALTHY AGEING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS **2018**, 14, P1280-P1281

41 P2-360: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM **2018**, 14, P827-P829

40 P3-264: UNBIASED METHOD TO DETERMINE CUT-POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION **2018**, 14, P1176-P1177

39 O2-03-03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY **2018**, 14, P615-P617

38 O2-14-04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATE-ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY **2018**, 14, P657-P658

37 IC-P-093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS **2018**, 14, P79-P80

36 IC-P-033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE **2018**, 14, P37-P38

35 P3-342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI-STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES **2018**, 14, P1214-P1215

34 IC-P-032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI-STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES **2018**, 14, P36-P37

33 P3-277: IMPAIRMENT IN COMPLEX ACTIVITIES OF DAILY LIVING IS RELATED TO NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECIFIC REGIONS **2018**, 14, P1183-P1184

32 THUR 174 The magnify-ms study: mavenclad tablets in active rms. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, A23.1-A23 5.5

31 P3-348: POSTERIOR ATROPHY SCALE: NORMATIVE VALUES FOR ITALIAN POPULATION **2018**, 14, P1217-P1218

30 IC-P-122: THE NORMAL AGING BRAIN COLLECTION AMSTERDAM (NABCA): A COMPREHENSIVE COLLECTION OF POSTMORTEM IMAGING, NEUROPATHOLOGICAL AND MORPHOMETRIC DATASETS **2018**, 14, P103-P104

29 IC-P-110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE **2018**, 14, P94-P95

28 F5-05-04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P1633-P1633

27 P1-467: DISEASE-STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P500-P501

26 O2-09-05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES **2018**, 14, P643-P643

25 P3-422: PROTOCOL HARMONISATION AND IN-VIVO COMPARISON OF ARTERIAL SPIN LABELLING PERFUSION MRI FOR MULTICENTER CLINICAL TRIALS **2018**, 14, P1269-P1271

24 O2-15-04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS **2018**, 14, P661-P662

23 O5-01-03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NON-NEGATIVE MATRIX FACTORIZATION **2018**, 14, P1638-P1639

22 IC-P-005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [18F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS **2018**, 14, P16-P17

21 O2-13-03: REGIONAL DISTRIBUTION OF WHITE MATTER HYPERINTENSITIES RELATED TO ALZHEIMER'S DISEASE RISK FACTORS IN THE ALFA COHORT **2018**, 14, P653-P654

20 F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION **2018**, 14, P201-P202

19 IC-P-053: LOWER STRUCTURAL DEGREE AND HIGHER LOCAL EFFICIENCY RELATED TO DIFFUSE AMYLOID-BETA LOAD IN CORTEX OF NON-NEUROLOGICAL AGED DONORS **2018**, 14, P51-P51

18 P3-355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [18F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS **2018**, 14, P1221-P1222

17 P2-477: THE NORMAL AGING BRAIN COLLECTION AMSTERDAM (NABCA): A COMPREHENSIVE COLLECTION OF POSTMORTEM IMAGING, NEUROPATHOLOGICAL AND MORPHOMETRIC DATASETS **2018**, 14, P907-P908

16 F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO A APOE 4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P201-P201

15 Neuroimaging in Dementia **2018**, 1-31

14 P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P895-P896

13 F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P202-P204

12 IC-P-187: CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS **2018**, 14, P156-P156

11 Neurodegenerative Disorders: Classification and Imaging Strategy **2018**, 1-26

10 Neuroimaging in Normal Brain Aging **2018**, 1-17

9	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. *Cerebral Circulation - Cognition and Behavior*, **2022**, 3, 100128	0
8	Response to the 'Letter to the editor'-10.1007/s00234-022-02906-z.. *Neuroradiology*, **2022**, 64, 849	3.2
7	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784	
6	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784	
5	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784	
4	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784	
3	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification.. *Alzheimeris and Dementia*, **2021**, 17 Suppl 3, e053030	1.2
2	Familial British dementia: a clinical and multi-modal imaging case study.. *Journal of Neurology*, **2022**, 1	5.5
1	Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.. *Radiology*, **2022**, 211252	20.5